

Michele Cavo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9342774/publications.pdf>

Version: 2024-02-01

884
papers

51,135
citations

2101

100
h-index

1934

207
g-index

906
all docs

906
docs citations

906
times ranked

23530
citing authors

#	ARTICLE	IF	CITATIONS
1	Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. <i>Blood</i> , 2022, 139, 492-501.	1.4	64
2	Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. <i>Blood</i> , 2022, 139, 835-844.	1.4	43
3	Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. <i>British Journal of Haematology</i> , 2022, 196, 639-648.	2.5	7
4	A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. <i>Blood Advances</i> , 2022, 6, 327-338.	5.2	28
5	INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 1742-1753.	5.2	33
6	Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients. <i>European Journal of Haematology</i> , 2022, 108, 178-189.	2.2	5
7	How I treat high-risk multiple myeloma. <i>Blood</i> , 2022, 139, 2889-2903.	1.4	17
8	Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, 15.	6.2	14
9	Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells. <i>Cancers</i> , 2022, 14, 738.	3.7	1
10	Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia. <i>OncoTargets and Therapy</i> , 2022, Volume 15, 103-116.	2.0	6
11	Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. <i>Lancet Haematology</i> , 2022, 9, e98-e110.	4.6	32
12	Management of infectious risk of daratumumab therapy in multiple myeloma: A consensus-based position paper from an ad hoc Italian expert panel. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103623.	4.4	7
13	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. <i>Lancet Oncology</i> , 2022, 23, 416-427.	10.7	54
14	Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis. <i>Advances in Therapy</i> , 2022, 39, 1976-1992.	2.9	10
15	LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. <i>Leukemia</i> , 2022, 36, 1371-1376.	7.2	81
16	Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma. <i>Frontiers in Oncology</i> , 2022, 12, 851864.	2.8	9
17	Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis. <i>Cancer</i> , 2022, 128, 2449-2454.	4.1	7
18	Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors. <i>American Journal of Hematology</i> , 2022, 97, 877-884.	4.1	12

#	ARTICLE	IF	CITATIONS
19	Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity. <i>Leukemia Research</i> , 2022, 116, 106819.	0.8	5
20	Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia. <i>Cancer Medicine</i> , 2022, 11, 618-629.	2.8	3
21	Release of IFN γ by Acute Myeloid Leukemia Cells Remodels Bone Marrow Immune Microenvironment by Inducing Regulatory T Cells. <i>Clinical Cancer Research</i> , 2022, 28, 3141-3155.	7.0	20
22	Prof. Sante Tura: Father of modern Italian haematology 20 May, 1929â€“12 October, 2021. <i>Leukemia</i> , 2022, 36, 1446-1447.	7.2	0
23	Prof. Sante Tura: father of modern Italian Haematology 20 May, 1929 to 12 October, 2021. <i>Bone Marrow Transplantation</i> , 2022, , .	2.4	0
24	Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2022, 9, e403-e414.	4.6	23
25	Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3â€­year followâ€­up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials. <i>Hematological Oncology</i> , 2022, 40, 704-715.	1.7	6
26	Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. <i>Journal of Clinical Oncology</i> , 2022, 40, 3406-3418.	1.6	115
27	Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment. <i>Hematological Oncology</i> , 2022, 40, 734-742.	1.7	3
28	Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. <i>Hematological Oncology</i> , 2022, 40, 1020-1029.	1.7	6
29	Early Light Chains Removal and Albumin Levels with a Double Filter-Based Extracorporeal Treatment for Acute Myeloma Kidney. <i>Toxins</i> , 2022, 14, 391.	3.4	1
30	: A copy number clustering tool designed to refit and recalibrate the baseline region of tumorsâ€™ profiles. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 3718-3728.	4.1	0
31	Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients. <i>Annals of Hematology</i> , 2021, 100, 2261-2268.	1.8	4
32	BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS. <i>Leukemia</i> , 2021, 35, 2102-2107.	7.2	8
33	Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression. <i>Haematologica</i> , 2021, 106, 1943-1956.	3.5	46
34	Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies. <i>Haematologica</i> , 2021, 106, 1079-1085.	3.5	12
35	Standardization of ¹⁸ F-FDGâ€™PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 116-125.	1.6	85
36	Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. <i>Blood</i> , 2021, 137, 1154-1165.	1.4	49

#	ARTICLE	IF	CITATIONS
37	A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma. <i>Hematological Oncology</i> , 2021, 39, 41-50.	1.7	22
38	Second primary malignancy in myelofibrosis patients treated with ruxolitinib. <i>British Journal of Haematology</i> , 2021, 193, 356-368.	2.5	19
39	Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 757-767.	1.6	98
40	Successful stem cell harvest and autologous transplantation in a patient with cold agglutinin syndrome and aggressive lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1007-1009.	1.3	3
41	Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID-19) pandemic: selection criteria and patients' satisfaction. <i>British Journal of Haematology</i> , 2021, 192, e48-e51.	2.5	14
42	Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2021, 35, 31-44.	7.2	79
43	Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 619-631.	2.5	17
44	Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 271-279.	2.5	4
45	Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. <i>Blood Cancer Journal</i> , 2021, 11, 4.	6.2	41
46	Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 49.	8.6	11
47	Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2021, 384, 705-716.	27.0	1,129
48	Sunitinib Exerts In Vitro Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade. <i>Frontiers in Immunology</i> , 2021, 12, 577766.	4.8	16
49	Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients. <i>Leukemia Research</i> , 2021, 101, 106497.	0.8	3
50	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	2.5	67
51	Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. <i>Hematological Oncology</i> , 2021, 39, 409-418.	1.7	9
52	Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e119-e130.	10.7	92
53	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	10.7	136
54	Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 309-322.	1.2	316

#	ARTICLE	IF	CITATIONS
55	Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study. <i>Leukemia and Lymphoma</i> , 2021, 62, 1897-1906.	1.3	1
56	Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a. <i>Biomedicines</i> , 2021, 9, 388.	3.2	6
57	Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 59.	17.0	11
58	Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. <i>Cancer</i> , 2021, 127, 2657-2665.	4.1	14
59	Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia. <i>Blood</i> , 2021, 138, 571-583.	1.4	26
60	Effect of age and frailty on the efficacy and tolerability of once-a-week selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 708-718.	4.1	16
61	Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 8042-8042.	1.6	5
62	Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement. <i>Acta Haematologica</i> , 2021, 144, 688-692.	1.4	1
63	Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial. <i>Blood Cancer Journal</i> , 2021, 11, 106.	6.2	31
64	Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations. <i>Leukemia</i> , 2021, 35, 2813-2826.	7.2	15
65	Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial. <i>BMC Cancer</i> , 2021, 21, 659.	2.6	8
66	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. <i>Lancet</i> , The, 2021, 397, 2361-2371.	13.7	177
67	Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 785-798.	0.4	22
68	SYSTEMIC MASTOCYTOSIS: MOLECULAR LANDSCAPE AND IMPLICATIONS FOR TREATMENT. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2021, 13, e2021046.	1.3	2
69	The diagnostic role of Next Generation Sequencing in uncovering isolated splenomegaly: A case report. <i>Hematology Reports</i> , 2021, 13, 8814.	0.8	0
70	Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 801-812.	10.7	162
71	Expanding CD38-targeting triplets for relapsed or refractory multiple myeloma. <i>Lancet</i> , The, 2021, 397, 2311-2313.	13.7	0
72	The Role of Hypoxic Bone Marrow Microenvironment in Acute Myeloid Leukemia and Future Therapeutic Opportunities. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6857.	4.1	11

#	ARTICLE	IF	CITATIONS
73	Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone. <i>American Journal of Hematology</i> , 2021, 96, E383-E386.	4.1	7
74	2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. <i>Haematologica</i> , 2021, 106, 2799-2812.	3.5	22
75	Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. <i>American Journal of Hematology</i> , 2021, 96, 1120-1130.	4.1	15
76	COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. <i>British Journal of Haematology</i> , 2021, 195, 371-377.	2.5	56
77	Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2430-2442.	1.6	53
78	Skeletal Survey in Multiple Myeloma: Role of Imaging. <i>Current Medical Imaging</i> , 2021, 17, 956-965.	0.8	3
79	Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 728613.	2.8	4
80	MM-171: Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S426-S427.	0.4	0
81	The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: "Crafting" a Microenvironment That Matters. <i>Cells</i> , 2021, 10, 2316.	4.1	8
82	An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia. <i>Blood Advances</i> , 2021, , .	5.2	12
83	Early low-dose computed tomography with pulmonary angiography to improve the early diagnosis of invasive mould disease in patients with haematological malignancies: A pilot study. <i>Journal of Infection</i> , 2021, 83, 371-380.	3.3	4
84	Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3613-3622.	1.6	25
85	Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy. <i>Advances in Therapy</i> , 2021, 38, 1328-1341.	2.9	2
86	Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. <i>HemaSphere</i> , 2021, 5, e528.	2.7	45
87	Emerging Bone Marrow Microenvironment-Driven Mechanisms of Drug Resistance in Acute Myeloid Leukemia: Tangle or Chance?. <i>Cancers</i> , 2021, 13, 5319.	3.7	15
88	Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients. <i>Expert Review of Hematology</i> , 2021, , 1-14.	2.2	1
89	A Specific Host/Microbial Signature of Plasma-Derived Extracellular Vesicles Is Associated to Thrombosis and Marrow Fibrosis in Polycythemia Vera. <i>Cancers</i> , 2021, 13, 4968.	3.7	0
90	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. <i>Lancet Haematology</i> , the, 2021, 8, e934-e946.	4.6	46

#	ARTICLE	IF	CITATIONS
91	P-053: BoBafit: a Copy Number-clustering tool to refit and recalibrate the diploid region of Multiple Myeloma genomic profiles. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S67.	0.4	0
92	An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera. <i>Frontiers in Oncology</i> , 2021, 11, 715217.	2.8	7
93	Prediction of Early Death and Severe Infections during Novel Agent-Based Induction Therapy in Newly-Diagnosed Multiple Myeloma: An Intergroup Analysis from the German Speaking Myeloma Multicenter Group, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology Foundation and the European Myeloma Network. <i>Blood</i> , 2021, 138, 3792-3792.	1.4	0
94	IDH1/2 Mutations Are Maintained in a Subset of Patients with Acute Myeloid Leukemia in Complete Remission and Do Not Correlate with Residual Disease. <i>Blood</i> , 2021, 138, 4446-4446.	1.4	0
95	LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma Who Received ≥3 Prior Lines of Therapy. <i>Blood</i> , 2021, 138, 3057-3057.	1.4	1
96	Impact of Comorbidities on Prognosis of Elderly Patients with Acute Myeloid Leukemia Who Receive Hypomethylating Agents. <i>Blood</i> , 2021, 138, 3373-3373.	1.4	0
97	The Accuracy of the International Myeloma Working Group Frailty Score in Capturing Health-Related Quality of Life Profile of Patients with Relapsed Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 115-115.	1.4	2
98	Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-Related Quality of Life for Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Final Data from the Phase 2 ELOQUENT-3 Trial. <i>Blood</i> , 2021, 138, 1662-1662.	1.4	2
99	Efficacy and Safety of Ruxolitinib in the Treatment of Elderly Patients with Polycythemia Vera Resistant/Intolerant to Hydroxyurea. <i>Blood</i> , 2021, 138, 2581-2581.	1.4	1
100	An Outpatient Management for First Cycle of Venetoclax and Hypomethylating Agents Results in Reduced Infection Rate and Hospitalizations in Acute Myeloid Leukemia Patients. <i>Blood</i> , 2021, 138, 2340-2340.	1.4	1
101	Spleen and Liver Fibrosis Is Associated to Treatment Response and Prognosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms. <i>Blood</i> , 2021, 138, 3626-3626.	1.4	0
102	Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd). <i>Blood</i> , 2021, 138, 1634-1634.	1.4	1
103	Role of Mir-192-5p during Response to Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes. <i>Blood</i> , 2021, 138, 3673-3673.	1.4	0
104	High Humoral Response after Anti-Sars-Cov-2 mRNA-Based Vaccines in Patients with Active Multiple Myeloma (MM) and Relationship with Disease Status/Line of Therapy. <i>Blood</i> , 2021, 138, 4732-4732.	1.4	1
105	Circulating Extracellular Vesicles from Acute Myeloid Leukemia Patients Drive Distinct Metabolic Profile of Leukemic Cells and Reveal Crucial Lipidomic Biomarkers. <i>Blood</i> , 2021, 138, 3471-3471.	1.4	1
106	Safety of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Patients with Multiple Myeloma Presenting with Extramedullary Disease during the COVID-19 Pandemic. <i>Blood</i> , 2021, 138, 1657-1657.	1.4	0
107	Carfilzomib, Pomalidomide and Dexamethasone (KpD) in Patients with First Progression of Multiple Myeloma Refractory to Bortezomib and Lenalidomide. Final Report of the EMN011/HOVON114 Trial. <i>Blood</i> , 2021, 138, 1664-1664.	1.4	6
108	Efficacy and Safety of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment or on Dialysis: Final Analysis of the Phase 2 Dare Study. <i>Blood</i> , 2021, 138, 2729-2729.	1.4	1

#	ARTICLE	IF	CITATIONS
109	Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 84-84.	1.4	16
110	Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1705-1720.	10.7	120
111	OAB-041: Epithelial-mesenchymal-transition regulated by Junctional Adhesion Molecule-A (JAM-A) associates with aggressive extramedullary multiple myeloma disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S26-S27.	0.4	1
112	OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S4-S5.	0.4	0
113	P-164: Safety of lenalidomide (LEN)-based therapy vs non-LEN-based therapy for transplant-ineligible newly diagnosed multiple myeloma (TNE NDMM): update from the post-authorization study MM-034. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S125-S126.	0.4	0
114	OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S17-S18.	0.4	7
115	OAB-059: Towards a comprehensive multimodal minimal residual disease assessment in multiple myeloma: the role of circulating cell-free DNA to define the extent of disease spreading. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S37.	0.4	1
116	OAB-057: Temporal-weight estimation of the copy number alterations of 1384 Multiple Myeloma patients defines an ancestrality index impacting patients survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S35-S36.	0.4	0
117	Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters. <i>Frontiers in Immunology</i> , 2021, 12, 804988.	4.8	5
118	Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS-13 activity and autoantibodies. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12606.	2.3	1
119	Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. <i>Haematologica</i> , 2020, 105, 468-477.	3.5	41
120	Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. <i>Haematologica</i> , 2020, 105, 193-200.	3.5	29
121	Idelalisib as a Bridge to Allogeneic Transplantation in Relapsed/Refractory Lymphoma With Renal Cancer: A Case Report. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e15-e17.	0.4	2
122	A matching-adjusted indirect treatment comparison (MAIC) of daratumumab+ bortezomib+ melphalan+ prednisone (D-VMP) versus lenalidomide+ dexamethasone continuous (Rd continuous), lenalidomide+ dexamethasone 18 months (Rd 18), and melphalan+ prednisone+ thalidomide (MPT). <i>Leukemia and Lymphoma</i> , 2020, 61, 714-720.	1.3	3
123	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. <i>Cancer</i> , 2020, 126, 1243-1252.	4.1	106
124	Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2020, 395, 132-141.	18.7	299
125	The timing of plerixafor addition to G-CSf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2020, 55, 946-954.	2.4	3
126	Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years. <i>Thrombosis Research</i> , 2020, 185, 88-95.	1.7	7

#	ARTICLE	IF	CITATIONS
127	Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy. <i>Cell Metabolism</i> , 2020, 32, 829-843.e9.	16.2	122
128	Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis. <i>Advances in Therapy</i> , 2020, 37, 4996-5009.	2.9	2
129	The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis. <i>Oncolmmunology</i> , 2020, 9, 1782575.	4.6	20
130	Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. <i>Lancet Haematology,the</i> , 2020, 7, e861-e873.	4.6	34
131	Denatonium as a Bitter Taste Receptor Agonist Modifies Transcriptomic Profile and Functions of Acute Myeloid Leukemia Cells. <i>Frontiers in Oncology</i> , 2020, 10, 1225.	2.8	14
132	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. <i>Lancet Haematology,the</i> , 2020, 7, e737-e745.	4.6	430
133	P1693LONG-TERM OUTCOME OF KIDNEY TRANSPLANTATION IN PLASMA CELLS DYSCRASIAS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
134	Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2020, 21, 1630-1642.	10.7	237
135	Effectiveness of chemotherapy after anti-CD19 blockade failure for relapsed and refractory Hodgkin lymphoma. <i>Cancer Medicine</i> , 2020, 9, 7830-7836.	2.8	17
136	A Screening of Antineoplastic Drugs for Acute Myeloid Leukemia Reveals Contrasting Immunogenic Effects of Etoposide and Fludarabine. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6802.	4.1	5
137	Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience. <i>Hematological Oncology</i> , 2020, 38, 737-741.	1.7	7
138	Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. <i>Journal of Hematology and Oncology</i> , 2020, 13, 115.	17.0	32
139	ALL-073: Inotuzumab Ozogamicin (IO) and Donor Lymphocyte Infusion (DLI) are a Safe and Promising Combination in Relapsed Acute Lymphoblastic Leukemia (ALL) After Allogeneic Hematopoietic Stem Cell Transplant (HSCT). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S161.	0.4	1
140	CML-206: ReSETting SETD2/H3K36Me3 Deficiency as a New Therapeutic Strategy in Blast Crisis Chronic Myeloid Leukemia Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S236-S237.	0.4	0
141	MM-133: HORIZON (OP-106): Melflufen Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody (mAb) - Final Primary Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S295-S296.	0.4	0
142	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2020, 396, 1563-1573.	13.7	188
143	Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 3519.	2.4	19
144	Elderly Non-GCB Diffuse Large B-Cell Lymphoma Patient Responding to Lenalidomide after Epicardial Relapse: A Case Report. <i>Acta Haematologica</i> , 2020, 143, 594-597.	1.4	1

#	ARTICLE	IF	CITATIONS
145	Disease-Specific Derangement of Circulating Endocannabinoids and N-Acylethanolamines in Myeloproliferative Neoplasms. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3399.	4.1	4
146	Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3987.	4.1	20
147	câ€MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomideâ€dexamethasone in myeloma. <i>European Journal of Haematology</i> , 2020, 105, 35-46.	2.2	8
148	MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia. <i>European Journal of Haematology</i> , 2020, 105, 47-55.	2.2	4
149	Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis. <i>Blood Cancer Journal</i> , 2020, 10, 35.	6.2	16
150	Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review. <i>BMC Cancer</i> , 2020, 20, 170.	2.6	14
151	Bendamustineâ€rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients. <i>Hematological Oncology</i> , 2020, 38, 487-492.	1.7	11
152	Management of central nervous system relapse in a young patient affected by primary mediastinal large Bâ€cell lymphoma: A case report. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 933-937.	0.5	4
153	Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). <i>Leukemia</i> , 2020, 34, 1840-1852.	7.2	55
154	Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma. <i>Bone Marrow Transplantation</i> , 2020, 55, 1865-1867.	2.4	4
155	Comparison of efficacy from two different dosing regimens of bortezomib: an exposureâ€response analysis. <i>British Journal of Haematology</i> , 2020, 189, 860-868.	2.5	3
156	⁹⁰Yâ€ibritumomab tiuxetan in patients with extraâ€nodal marginal zone Bâ€cell lymphoma of mucosaâ€associated lymphoid tissue (MALT lymphoma) â€” The Zeno Study. <i>British Journal of Haematology</i> , 2020, 189, e6-e9.	2.5	6
157	Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis. <i>Hematological Oncology</i> , 2020, 38, 201-203.	1.7	2
158	Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. <i>Haematologica</i> , 2020, 106, 291-294.	3.5	17
159	Autologous haematopoietic stem-cell transplantation versus bortezomibâ€melphalanâ€prednisone, with or without bortezomibâ€lenalidomideâ€dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. <i>Lancet Haematology</i> , the, 2020, 7, e456-e468.	4.6	244
160	Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. <i>Lancet Haematology</i> , the, 2020, 7, e370-e380.	4.6	170
161	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Realâ€world data. <i>Hematological Oncology</i> , 2020, 38, 372-380.	1.7	15
162	Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. <i>Leukemia</i> , 2020, 34, 3019-3027.	7.2	17

#	ARTICLE	IF	CITATIONS
163	Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 489.	4.8	90
164	Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. <i>Blood</i> , 2020, 135, 534-541.	1.4	61
165	Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. <i>Blood Advances</i> , 2020, 4, 830-844.	5.2	54
166	Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 480-489.	0.4	7
167	Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial. <i>Blood</i> , 2020, 136, 35-37.	1.4	37
168	A New Risk Stratification Model (R2-ISS) in Newly Diagnosed Multiple Myeloma: Analysis of Mature Data from 7077 Patients Collected By European Myeloma Network within Harmony Big Data Platform. <i>Blood</i> , 2020, 136, 34-37.	1.4	12
169	Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study. <i>Blood</i> , 2020, 136, 50-52.	1.4	1
170	Potential Disease-Modifying Activity of Imetelstat Demonstrated By Reduction in Cytogenetically Abnormal Clones and Mutation Burden Leads to Clinical Benefits in Relapsed/Refractory Myelofibrosis Patients. <i>Blood</i> , 2020, 136, 39-40.	1.4	9
171	Correlation Analyses of Imetelstat Exposure with Pharmacodynamic Effect, Efficacy and Safety in a Phase 2 Study in Patients with Higher-Risk Myelofibrosis Refractory to Janus Kinase Inhibitor Identified an Optimal Dosing Regimen for Phase 3 Study. <i>Blood</i> , 2020, 136, 33-34.	1.4	1
172	Sequential Analysis of miRNA Profiling during Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes. <i>Blood</i> , 2020, 136, 6-7.	1.4	0
173	HORIZON (OP-106) Versus MAMMOTH: An Indirect Comparison of Efficacy Outcomes for Patients with Relapsed/Refractory Multiple Myeloma Refractory (RRMM) to Anti-CD38 Monoclonal Antibody Therapy Treated with Melflufen Plus Dexamethasone Versus Conventional Agents. <i>Blood</i> , 2020, 136, 2-4.	1.4	4
174	Azacitidine and Lenalidomide in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study and Impact of Cytogenetic Scores and Mutational Status on Long-Lasting Responses. <i>Blood</i> , 2020, 136, 45-45.	1.4	0
175	A Screening of Antineoplastic Drugs for Acute Myeloid Leukemia Reveals That Fludarabine Has Weak Immunogenic Capacity and Induces T Regulatory Cells. <i>Blood</i> , 2020, 136, 5-5.	1.4	0
176	Treatment with Imetelstat Improves Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in Patients with Relapsed or Refractory Higher-Risk Myelofibrosis. <i>Blood</i> , 2020, 136, 45-46.	1.4	21
177	Saprochaete clavata infections in patients undergoing treatment for haematological malignancies: A report of a monocentric outbreak and review of the literature. <i>Mycoses</i> , 2019, 62, 1100-1107.	4.0	19
178	Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e448-e458.	4.6	168
179	Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e459-e469.	4.6	174
180	BRAF V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4807-4812.	2.0	4

#	ARTICLE	IF	CITATIONS
181	Multiple Myeloma: Clinical Aspects. , 2019, , 1-13.		1
182	Spontaneous remission of follicular lymphoma. Hematological Oncology, 2019, 37, 626-627.	1.7	4
183	A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e31.	0.4	18
184	The Yin and Yang of the Bone Marrow Microenvironment: Pros and Cons of Mesenchymal Stromal Cells in Acute Myeloid Leukemia. Frontiers in Oncology, 2019, 9, 1135.	2.8	30
185	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet, The, 2019, 394, 2096-2107.	13.7	435
186	Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations. Blood Reviews, 2019, 34, 84-94.	5.7	35
187	Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia. Frontiers in Oncology, 2019, 9, 1004.	2.8	23
188	HORIZON (OP-106) Study of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Daratumumab and/or Pomalidomide: Updated Efficacy and Safety. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S329-S330.	0.4	2
189	Successful Employment of Brentuximab Vedotin in a Patient Undergoing Hemodialysis: The First Real-life Experience. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e595-e596.	0.4	8
190	Liver Stiffness Measurement Allows Early Diagnosis of Venous Occlusive Disease/Sinusoidal Obstruction Syndrome in Adult Patients Who Undergo Hematopoietic Stem Cell Transplantation: Results from a Monocentric Prospective Study. Biology of Blood and Marrow Transplantation, 2019, 25, 995-1003.	2.0	56
191	Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis. Annals of Hematology, 2019, 98, 1933-1936.	1.8	5
192	International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncology, The, 2019, 20, e302-e312.	10.7	290
193	Understanding mortality in multiple myeloma: Findings of a European retrospective chart review. European Journal of Haematology, 2019, 103, 107-115.	2.2	23
194	Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors. Journal of Experimental and Clinical Cancer Research, 2019, 38, 216.	8.6	11
195	Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma. Current Hematologic Malignancy Reports, 2019, 14, 187-196.	2.3	8
196	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 781-794.	10.7	254
197	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. Hematological Oncology, 2019, 37, 418-423.	1.7	3
198	PD-1 blockade as bridge to allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series. Haematologica, 2019, 104, e521-e522.	3.5	5

#	ARTICLE	IF	CITATIONS
199	Development and internal validation of a model for predicting 60-day risk of invasive mould disease in patients with haematological malignancies. <i>Journal of Infection</i> , 2019, 78, 484-490.	3.3	20
200	Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes. <i>Leukemia</i> , 2019, 33, 2276-2290.	7.2	25
201	Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. <i>Journal of Internal Medicine</i> , 2019, 286, 63-74.	6.0	42
202	Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies. <i>Haematologica</i> , 2019, 104, 1640-1647.	3.5	22
203	Insights on Multiple Myeloma Treatment Strategies. <i>HemaSphere</i> , 2019, 3, e163.	2.7	33
204	PB1699 A SCREENING OF ANTINEOPLASTIC DRUGS FOR ACUTE MYELOID LEUKEMIA REVEALS THAT FLUDARABINE AND CYTARABINE HAVE WEAK CAPACITY AS INDUCERS OF IMMUNOGENIC CELL DEATH. <i>HemaSphere</i> , 2019, 3, 782-783.	2.7	0
205	S1605 HORIZON (OPâ€106): UPDATED EFFICACY AND SAFETY OF MELFLUFEN IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO DARATUMUMAB (DARA) AND/OR POMALIDOMIDE (POM). <i>HemaSphere</i> , 2019, 3, 739.	2.7	1
206	PS1420 RESULTS FROM A POST-AUTHORIZATION SAFETY STUDY COMPARING LENALIDOMIDE-BASED WITH NONâ€LENALIDOMIDE-BASED TREATMENT IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS. <i>HemaSphere</i> , 2019, 3, 653-654.	2.7	0
207	Facing lenalidomide-refractory myeloma. <i>Blood</i> , 2019, 134, 99-101.	1.4	4
208	Rare, but complex chromosomal rearrangements, defined "Chromoanagenesisâ€", caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e78-e79.	0.4	0
209	Greater Treatment Satisfaction in Patients Receiving Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) for Relapsed or Refractory Multiple Myeloma (RRMM): COLUMBA. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e247-e248.	0.4	2
210	Post-Authorization Safety Study of Lenalidomide-Based vs Nonâ€Lenalidomide-Based Treatment in Transplant-Ineligible Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e226-e227.	0.4	0
211	Analysis of the genomic and transcriptomic landscape of chemoresistant multiple myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e58-e59.	0.4	0
212	VarianThinker: a classification method to confidently approach the mutation heterogeneity in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e72-e73.	0.4	0
213	PF172â€PROSPECTIVE COMPARISON OF SANGER SEQUENCING VS NEXT GENERATION SEQUENCING FOR ROUTINE BCRâ€ABL1â€KINASE DOMAIN MUTATION SCREENING IN PHILADELPHIAâ€POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS. <i>HemaSphere</i> , 2019, 3, 37-38.		0
214	PB1726 DOUBLE FLUDARABINEâ€BASED INDUCTION AND INFECTIVE RISK: THE BOLOGNA EXPERIENCE.. <i>HemaSphere</i> , 2019, 3, 794.	2.7	0
215	Frontâ€line treatment of multiple myeloma. <i>HemaSphere</i> , 2019, 3, 127-130.	2.7	4
216	PS1349 UPDATED RISK STRATIFICATION MODEL FOR SMOLDERING MULTIPLE MYELOMA (SMM) INCORPORATING THE REVISED IMWG DIAGNOSTIC CRITERIA. <i>HemaSphere</i> , 2019, 3, 616.	2.7	1

#	ARTICLE	IF	CITATIONS
217	Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6141.	4.1	63
218	A Maturation Index defines Newly Diagnosed Multiple Myeloma Patients with advanced immunophenotypic and Molecular Differentiation profiles associated with poor prognosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e69-e70.	0.4	0
219	Imaging in multiple myeloma: How? When?. <i>Blood</i> , 2019, 133, 644-651.	1.4	82
220	Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis. <i>Cancer</i> , 2019, 125, 750-760.	4.1	31
221	Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis. <i>British Journal of Haematology</i> , 2019, 185, 987-991.	2.5	16
222	Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery. <i>Cancer</i> , 2019, 125, 712-725.	4.1	49
223	Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients. <i>British Journal of Haematology</i> , 2019, 184, 424-430.	2.5	16
224	Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016. <i>British Journal of Haematology</i> , 2019, 185, 981-984.	2.5	18
225	A case report of the long treatment experience of a SÅ©zary syndrome responder patient: 16 years through all the systemic and innovative therapies. <i>Hematological Oncology</i> , 2019, 37, 202-204.	1.7	1
226	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. <i>Annals of Hematology</i> , 2019, 98, 889-896.	1.8	10
227	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 393, 253-264.	13.7	187
228	Intrabone transplant provides full stemness of cord blood stem cells with fast hematopoietic recovery and low GVHD rate: results from a prospective study. <i>Bone Marrow Transplantation</i> , 2019, 54, 717-725.	2.4	16
229	PS1395 COMPARATIVE EFFECTIVENESS OF FRONT-LINE TREATMENTS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE TRANSPLANT INELIGIBLE. <i>HemaSphere</i> , 2019, 3, 640.	2.7	1
230	Abstract 2651: Deep hypoxia and the genomic background cooperate to shape the metabolic profile of acute myeloid leukemia cells. , 2019, , .		1
231	The Genomic and Transcriptomic Landscape of Double-Refractory Multiple Myeloma. <i>Blood</i> , 2019, 134, 3056-3056.	1.4	1
232	Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study. <i>Blood</i> , 2019, 134, 3480-3480.	1.4	3
233	Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone. <i>Blood</i> , 2019, 134, 859-859.	1.4	18
234	A Network Meta-Analysis (NMA) to Evaluate Comparative Effectiveness of Frontline Treatments for Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (TIE). <i>Blood</i> , 2019, 134, 2144-2144.	1.4	1

#	ARTICLE	IF	CITATIONS
235	Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients. Blood, 2019, 134, 4322-4322.	1.4	15
236	Clinical Activity of Melflufen in Patients with Triple-Class Refractory Multiple Myeloma and Poor-Risk Features in an Updated Analysis of HORIZON (OP-106), a Phase 2 Study in Patients with Relapsed/Refractory Multiple Myeloma Refractory to Pomalidomide and/or Daratumumab. Blood, 2019, 134, 1883-1883.	1.4	8
237	MRD Evaluation By PET/CT According to Deauville Criteria Combined with Multiparameter Flow Cytometry in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients Enrolled in the Phase II Randomized Forte Trial. Blood, 2019, 134, 4321-4321.	1.4	8
238	Integrative Analysis of Baseline Prognostic Features and Achievement of Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients. Blood, 2019, 134, 605-605.	1.4	3
239	Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2019, 134, 1888-1888.	1.4	35
240	T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study. Blood, 2019, 134, 142-142.	1.4	25
241	Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Cimema CML 0307 Trial. Blood, 2019, 134, 4145-4145.	1.4	3
242	Adhesion-Mediated Multiple Myeloma (MM) Disease Progression: Junctional Adhesion Molecule a Enhances Angiogenesis and Multiple Myeloma Dissemination and Predicts Poor Survival. Blood, 2019, 134, 855-855.	1.4	7
243	Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making. Blood, 2019, 134, 661-661.	1.4	5
244	Negative Selective Pressure Exerted By Maintenance Therapy Promotes the Extinction of Sub-Clones Carrying High-Risk Lesions in Multiple Myeloma. Blood, 2019, 134, 1778-1778.	1.4	1
245	Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial.. Journal of Clinical Oncology, 2019, 37, 8002-8002.	1.6	67
246	Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR.. Journal of Clinical Oncology, 2019, 37, 8040-8040.	1.6	1
247	PS1437 SETD2-GENOMIC LOSS OF FUNCTION IN ADVANCED SYSTEMIC MASTOCYTOSIS (SM): PATHOGENETIC AND THERAPEUTIC IMPLICATIONS. HemaSphere, 2019, 3, 662-663.	2.7	0
248	PB2324-LONG TERM OUTCOME OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS: THE ROLE OF MINIMAL RESIDUAL DISEASE. HemaSphere, 2019, 3, 1036.	2.7	0
249	PF602 OUTCOME OF EXTRA-MEDULLARY DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NEW DRUGS. HemaSphere, 2019, 3, 254-255.	2.7	0
250	PS1382 DEEPENING RESPONSES SEEN WITH IXAZOMIB MAINTENANCE POST-AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) ARE ASSOCIATED WITH PROLONGED PROGRESSION-FREE SURVIVAL ANALYSIS FROM THE TOURMALINE-MM3 STUDY. HemaSphere, 2019, 3, 632-633.	2.7	0
251	Abstract 473: Higher levels of genomic complexity correlates with an advanced plasma cell differentiation status in newly diagnosed multiple myeloma patients. , 2019, , .		0
252	Abstract CT154: Melflufen in patients (pts) with relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab (dara) and/or pomalidomide (pom) (OP-106). , 2019, , .		0

#	ARTICLE	IF	CITATIONS
253	Abstract 470: Chromosomal instability and bad prognosis both connote a multiple myeloma (MM) sub-type carrying 13qCN loss and 1qCN gain. , 2019, , .		0
254	Abstract 2964: Pharmacological inhibition of WIP1 by GSK2830371 sensitizes AML cells to MDM2 inhibitor Nutlin-3a. , 2019, , .		0
255	A Maturation Index Defines Newly Diagnosed Multiple Myeloma Patients with Advanced Immunophenotypic and Molecular Differentiation Profiles Associated with Poor Prognosis. Blood, 2019, 134, 1797-1797.	1.4	0
256	Efficacy of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: An Interim Analysis of a Phase 2 Study (the DARE Study). Blood, 2019, 134, 1881-1881.	1.4	0
257	Comparison of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) with Standard of Care for Patients from Latin America with Newly Diagnosed Multiple Myeloma (NDMM) Who Were Transplant Ineligible: A Propensity Score Matching Analysis. Blood, 2019, 134, 2143-2143.	1.4	0
258	Validation and Improvement Opportunities of the Revised International Staging System for Multiple Myeloma: An Analysis on Mature Data from European Clinical Trials within the Harmony Big Data Platform. Blood, 2019, 134, 1773-1773.	1.4	1
259	Safety Profile for Lenalidomide-Based and Non-Lenalidomide-Based First-Line Therapy for Multiple Myeloma in Transplant Ineligible Patients: Real-World Evidence from a European Post-Authorization Safety Study. Blood, 2019, 134, 5580-5580.	1.4	0
260	Serum Free Light Chain Assay As an Additional Tool for Defining Response and Progressive Disease in Immunoglobulin Secretory Multiple Myeloma. Blood, 2019, 134, 1796-1796.	1.4	0
261	The Use of Venetoclax for Acute Myeloid Leukemia in a Real-Life Setting: A Multicenter National Experience. Blood, 2019, 134, 5098-5098.	1.4	0
262	Risk Factors for Progression to Blast Phase and Outcome in 589 Patients with Myelofibrosis Treated with Ruxolitinib: Real-World Evidence. Blood, 2019, 134, 4166-4166.	1.4	0
263	In Systemic Mastocytosis, Midostaurin Targets Both Kit and Aurora Kinase a Reverting H3K36Me3 Deficiency and Synergizes with Second-Generation Tyrosine Kinase Inhibitors. Blood, 2019, 134, 4204-4204.	1.4	0
264	Physical Function, Pain Severity, and Fatigue in Patients with Relapsed/Refractory Multiple Myeloma: Health-Related Quality of Life Results in Patients Receiving Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone. Blood, 2019, 134, 3177-3177.	1.4	0
265	The Treatment of Hairy Cell Leukemia with a Focus on Long Lasting Responders to Cladribine: A Thirty-Year Experience from the Institute of Hematology of Bologna. Blood, 2019, 134, 4005-4005.	1.4	0
266	Mechanisms of Tolerance Induction through T Regulatory Cells during Chemotherapy-Mediated Immunogenic Cell Death in Acute Myeloid Leukemia. Blood, 2019, 134, 2332-2332.	1.4	0
267	Vascular and Parenchymal Alterations of the Liver and Liver Surveillance in Patients Who Received Inotuzumab Ozogamicin As the Standard of Care for Relapse/Refractory Acute Lymphoblastic Leukemia. Blood, 2019, 134, 1343-1343.	1.4	1
268	Impact of Comorbidities and Body Mass Index in Patients with Polycythemia Vera: A PV-NET Real World Study. Blood, 2019, 134, 4184-4184.	1.4	1
269	The Infection-Driven Production/Secretion of Inflammatory Cytokines By Circulating Monocytes of Myelofibrosis Is Defective and Is Reactivated after In Vivo JAK1/2 Inhibition. Blood, 2019, 134, 1686-1686.	1.4	0
270	The Locomotion Study (MMY4001): A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment and Documented Disease Progression. Blood, 2019, 134, 5549-5549.	1.4	1

#	ARTICLE	IF	CITATIONS
271	AML-CM Score Predicts Prognosis in Hemato-Geriatric Patients with New-Onset Acute Myeloid Leukemia (AML) Who Receive Hypomethylating Agents (HMA). <i>Blood</i> , 2019, 134, 2617-2617.	1.4	0
272	Interferon- β -Dependent Inflammatory Signature in Acute Myeloid Leukemia Cells Is Able to Shape Stromal and Immune Bone Marrow Microenvironment. <i>Blood</i> , 2019, 134, 1212-1212.	1.4	2
273	Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients. <i>Blood</i> , 2019, 134, 3372-3372.	1.4	0
274	Aurora Kinase α /MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way. <i>Blood</i> , 2019, 134, 4142-4142.	1.4	0
275	An IDO1-Related 3-Gene Signature Predicts Overall Survival in Intermediate-Risk Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 5193-5193.	1.4	0
276	Chromothripsis in acute myeloid leukemia: biological features and impact on survival. <i>Leukemia</i> , 2018, 32, 1609-1620.	7.2	80
277	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. <i>Hematological Oncology</i> , 2018, 36, 561-569.	1.7	46
278	Hodgkin lymphoma presenting with paraneoplastic myasthenia: a case report. <i>Leukemia and Lymphoma</i> , 2018, 59, 2990-2993.	1.3	8
279	Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma. <i>Haematologica</i> , 2018, 103, e277-e278.	3.5	26
280	Treatment of Transplant Eligible Patients with Multiple Myeloma. <i>Hematologic Malignancies</i> , 2018, , 29-60.	0.2	1
281	Clinical Features and Treatment Outcomes of Primary Cutaneous B-cell Lymphomas: A Thirty-year Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 297-299.	0.4	1
282	The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe. <i>Expert Review of Hematology</i> , 2018, 11, 219-237.	2.2	28
283	Interpretation criteria for FDG PET/CT in multiple myeloma (IMPETUs): final results. IMPETUs (Italian) Tj ETQq1 1 0.784314 rgBT /Over 712-719.	6.4	95
284	The utility of contrast-enhanced hypodense sign for the diagnosis of pulmonary invasive mould disease in patients with haematological malignancies. <i>British Journal of Radiology</i> , 2018, 91, 20170220.	2.2	12
285	Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. <i>Molecular Cancer</i> , 2018, 17, 49.	19.2	146
286	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2018, 32, 1542-1560.	7.2	68
287	Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy. <i>Expert Review of Hematology</i> , 2018, 11, 423-435.	2.2	18
288	Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review. <i>Supportive Care in Cancer</i> , 2018, 26, 2075-2090.	2.2	21

#	ARTICLE	IF	CITATIONS
289	A targeted proteomics approach to amyloidosis typing. <i>Clinical Mass Spectrometry</i> , 2018, 7, 18-28.	1.9	3
290	Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1. <i>Leukemia</i> , 2018, 32, 2032-2036.	7.2	12
291	Comparison of <i>JAK2</i> ^{V617F} positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology. <i>Hematological Oncology</i> , 2018, 36, 269-275.	1.7	11
292	Efficacy and safety of ruxolitinib in intermediate- to high IPSS risk myelofibrosis patients: Results from an independent study. <i>Hematological Oncology</i> , 2018, 36, 285-290.	1.7	29
293	SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis. <i>Leukemia</i> , 2018, 32, 139-148.	7.2	28
294	Successful treatment of bilateral endogenous <i>Fusarium solani</i> endophthalmitis in a patient with acute lymphocytic leukaemia. <i>Mycoses</i> , 2018, 61, 53-60.	4.0	12
295	From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. <i>Haematologica</i> , 2018, 103, 197-211.	3.5	110
296	Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. <i>New England Journal of Medicine</i> , 2018, 378, 518-528.	27.0	747
297	Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. <i>Blood</i> , 2018, 131, 301-310.	1.4	216
298	Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study. <i>European Journal of Haematology</i> , 2018, 100, 10-19.	2.2	7
299	PSY17 - TREATMENT REGIMENS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE INELIGIBLE FOR STEM CELL TRANSPLANTATION: A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS. <i>Value in Health</i> , 2018, 21, S438.	0.3	0
300	Bones in Multiple Myeloma: Imaging and Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 638-646.	3.8	30
301	Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia. <i>BMC Cancer</i> , 2018, 18, 1117.	2.6	16
302	Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma – an IMWG Research Project. <i>Blood Cancer Journal</i> , 2018, 8, 123.	6.2	81
303	Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. <i>Blood Cancer Journal</i> , 2018, 8, 95.	6.2	59
304	Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. <i>Haematologica</i> , 2018, 103, 2079-2087.	3.5	225
305	A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 127.	2.4	6
306	Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. <i>Leukemia Research</i> , 2018, 74, 86-88.	0.8	23

#	ARTICLE	IF	CITATIONS
307	Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival. <i>Stem Cell Research and Therapy</i> , 2018, 9, 271.	5.5	63
308	European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. <i>Haematologica</i> , 2018, 103, 1772-1784.	3.5	86
309	A predictive model for risk of early grade 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. <i>Leukemia</i> , 2018, 32, 1404-1413.	7.2	53
310	Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventive Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e401-e419.	0.4	61
311	Low-Dose Anti-T Lymphoglobulin as Prophylaxis for Graft-versus-Host Disease in Unrelated Donor Transplantations for Acute Leukemias and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2450-2458.	2.0	8
312	Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). <i>Haematologica</i> , 2018, 103, 1422-1432.	3.5	70
313	Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2018, 11, 99.	17.0	35
314	Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. <i>British Journal of Haematology</i> , 2018, 183, 35-46.	2.5	7
315	Treatment optimization for multiple myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in <i>in vitro</i> and <i>ex vivo</i> models. <i>Haematologica</i> , 2018, 103, e602-e606.	3.5	2
316	Mobilized Peripheral Blood versus Cord Blood: Insight into the Distinct Role of Proinflammatory Cytokines on Survival, Clonogenic Ability, and Migration of CD34+ Cells. <i>Mediators of Inflammation</i> , 2018, 2018, 1-14.	3.0	3
317	A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report. <i>BMC Cancer</i> , 2018, 18, 645.	2.6	11
318	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study. <i>Seminars in Hematology</i> , 2018, 55, 248-255.	3.4	24
319	The Berlin-Frankfurt-Amsterdam protocol for the upfront treatment of aggressive lymphomas: The Bologna experience. <i>American Journal of Hematology</i> , 2018, 93, E209.	4.1	1
320	Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). <i>Leukemia</i> , 2018, 32, 1697-1712.	7.2	83
321	Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2018, 132, 155-155.	1.4	21
322	One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone. <i>Blood</i> , 2018, 132, 156-156.	1.4	20
323	Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials. <i>Blood</i> , 2018, 132, 257-257.	1.4	20
324	Efficacy and Feasibility of Dose/Schedule-Adjusted Rd-R Vs. Continuous Rd in Elderly and Intermediate-Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients: RV-MM-PI-0752 Phase III Randomized Study. <i>Blood</i> , 2018, 132, 305-305.	1.4	30

#	ARTICLE	IF	CITATIONS
325	Quality-of-Life Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab Plus Pomalidomide and Dexamethasone: Results from the Phase 2 Randomized Eloquent-3 Study. <i>Blood</i> , 2018, 132, 2288-2288.	1.4	4
326	Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM). <i>Blood</i> , 2018, 132, 121-121.	1.4	46
327	Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies. <i>Blood</i> , 2018, 132, 3288-3288.	1.4	10
328	Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies. <i>Blood</i> , 2018, 132, 124-124.	1.4	41
329	OP-106 Horizon " Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS. <i>Blood</i> , 2018, 132, 600-600.	1.4	12
330	Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM). <i>Blood</i> , 2018, 132, 1994-1994.	1.4	10
331	A Matching-Adjusted Indirect Treatment Comparison of Daratumumab-Bortezomib-Melphalan-Prednisone Versus Lenalidomide-Dexamethasone Continuous, Lenalidomide-Dexamethasone 18 Months, and Melphalan-Prednisone-Thalidomide. <i>Blood</i> , 2018, 132, 3551-3551.	1.4	1
332	Treatment Regimens for Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation: A Systematic Literature Review and Network Meta-Analysis. <i>Blood</i> , 2018, 132, 4741-4741.	1.4	2
333	Carfilzomib, Pomalidomide and Dexamethasone (Kpd) in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide. the EMN011 Trial. <i>Blood</i> , 2018, 132, 801-801.	1.4	26
334	Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) By Prior Lines. <i>Blood</i> , 2018, 132, 3244-3244.	1.4	1
335	Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels. <i>Blood</i> , 2018, 132, 685-685.	1.4	33
336	Quantitative Assessment of Indoleamine 2,3-Dioxygenase (IDO) Expression at Diagnosis Predicts Clinical Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 5261-5261.	1.4	2
337	Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients. <i>Blood</i> , 2018, 132, 4277-4277.	1.4	11
338	Bortezomib-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone before and after Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase 3 Gimema-MMY-3006 Study and Prognostic Score for Survival Outcomes. <i>Blood</i> , 2018, 132, 125-125.	1.4	10
339	Next Generation Sequencing-Based BCR-ABL1 Kinase Domain Mutation Screening in De Novo and Tyrosine Kinase Inhibitor-Resistant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of a Prospective Study. <i>Blood</i> , 2018, 132, 4078-4078.	1.4	1
340	Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing. <i>Blood</i> , 2018, 132, 789-789.	1.4	3
341	The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2018, 132, 44-44.	1.4	8
342	Comparison of Two Different Therapeutic Regimens with Azacitidine and Lenalidomide (Combined) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Randomized Phase II Multicenter Study. <i>Blood</i> , 2018, 132, 4365-4365.	1.4	1

#	ARTICLE	IF	CITATIONS
343	Once Weekly Versus Twice Weekly Carfilzomib Dosing in Patients with Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Efficacy and Safety Analyzed By Age Group. <i>Blood</i> , 2018, 132, 3277-3277.	1.4	2
344	Outcome of 472 Chronic Myeloid Leukemia Patients Treated with Frontline Nilotinib: A Gimema CML WP Analysis. <i>Blood</i> , 2018, 132, 458-458.	1.4	3
345	Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial. <i>Blood</i> , 2018, 132, 3186-3186.	1.4	3
346	Daratumumab plus bortezomib-melphalan-prednisone (VMP) in elderly (≥75 y) patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE). <i>Journal of Clinical Oncology</i> , 2018, 36, 8031-8031.	1.6	2
347	Impact of baseline renal function on efficacy and safety of daratumumab plus bortezomib-melphalan-prednisone (VMP) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE). <i>Journal of Clinical Oncology</i> , 2018, 36, e20024-e20024.	1.6	2
348	Phase III (IMROZ) study design: Isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM). <i>Journal of Clinical Oncology</i> , 2018, 36, TPS8055-TPS8055.	1.6	21
349	Abstract 2539: Antiapoptotic gene expression signature reveals a combined talk to prevent apoptosis: A model to choose the proper BH-3 mimetic drug. , 2018, , .		0
350	Abstract 2176: Whole-genome analysis of CNAs identifies four main evolution trajectories in multiple myeloma (MM) patients front-line treated with PI-based regimens. , 2018, , .		0
351	Abstract 1872: Pharmacological inhibition of WIP1 sensitizes AML cells to MDM2 inhibitors. , 2018, , .		0
352	Abstract 3387: The pliancy of plasma cell differentiation status conceals a gradient of chromosomal instability in newly diagnosed multiple myeloma patients. , 2018, , .		0
353	Abstract 1229: Clonal hematopoiesis of indeterminate potential (CHIP), centenarians and age-related cardiovascular risk: Is TET2 the culprit. , 2018, , .		1
354	Abstract 2951: Gene expression profiling identifies new adult "triple-negative" acute lymphoblastic leukemia (ALL) subgroups. , 2018, , .		0
355	Abstract 656: Distinct pattern of alterations in TP53 mutated/deleted and wild-type high risk acute myeloid leukemia (AML) patients: Identification of new "targetable" genes/pathways. , 2018, , .		0
356	Abstract 3788: Antigen presentation by MHC-I molecule and immune escape in acute myeloid leukemia with high burden of genomic aberrations. , 2018, , .		0
357	Extramedullary metastatic plasmacytoma in multiple myeloma. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2018, 153, 741-743.	0.8	0
358	Real-Life Management of Immune Thrombocytopenia in the Elderly: A Multicentre Study on 526 Patients. <i>Blood</i> , 2018, 132, 2433-2433.	1.4	0
359	Presentation and Outcome of 199 Patients with 2016 WHO Diagnosis of Early and Overt Primary Myelofibrosis Treated with Ruxolitinib. <i>Blood</i> , 2018, 132, 3052-3052.	1.4	0
360	A New Gene Expression Profile Signature CRLF2 Overexpression Based Identifies Novel Adult "Triple Negative" Acute Lymphoblastic Leukemia Subgroups. <i>Blood</i> , 2018, 132, 5284-5284.	1.4	0

#	ARTICLE	IF	CITATIONS
361	Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Induces Genetic Instability and Can be Therapeutically Targeted. <i>Blood</i> , 2018, 132, 1726-1726.	1.4	0
362	Mitoxantrone, Etoposide and Cytarabine (MEC) Can Induce Deep Complete Remission and Is an Effective Bridge Therapy to Allogeneic Transplantation (SCT) in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients. <i>Blood</i> , 2018, 132, 4036-4036.	1.4	2
363	Biology of Acute Myeloid Leukemia (AML) with Monosomy of Chromosome 7 or Loss of 7q. a Study on 487 Patients Analyzed By Gene Expression Profile (GEP), Single Nucleotide Polymorphism (SNP) Arrays and Metabolomics. <i>Blood</i> , 2018, 132, 2748-2748.	1.4	0
364	Bitter Taste Receptors System Is Expressed and Functional in Both HSCs and Leukemic Cells. <i>Blood</i> , 2018, 132, 2560-2560.	1.4	0
365	Negative Prognostic Relevance of a Specific 3-Gene Cluster in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy. <i>Blood</i> , 2018, 132, 4347-4347.	1.4	0
366	The Malignant Hemopoietic Clone of Triple Negative Patients with Myelofibrosis Shows in Vitro Functional Defects but Is Highly Responsive to the Pro-Survival Signals of Circulating Autologous Microvesicles. <i>Blood</i> , 2018, 132, 4334-4334.	1.4	0
367	Higher Expression of PALB2 Predict Poor Prognosis in AML Patients and Identifies Potential Targets of Synthetic Lethal Therapies. <i>Blood</i> , 2018, 132, 1507-1507.	1.4	6
368	Up-Regulation of Immune Tolerance Genes in Leukemic Mesenchymal Stromal Cells Is Induced By Acute Myeloid Leukemia Cells through an IFN-Gamma-Dependent Inflammatory Signaling. <i>Blood</i> , 2018, 132, 2579-2579.	1.4	0
369	Outcome of Soft-Tissue Plasmocytomas in Newly Diagnosed Multiple Myeloma Patients Treated with New Drugs. <i>Blood</i> , 2018, 132, 3235-3235.	1.4	0
370	Comparative Efficacy and Safety of Daratumumab in Combination with Bortezomib, Melphalan, and Prednisone (D-VMP) in Alcyone Versus Bortezomib, Melphalan, and Prednisone (VMP) in Vista in Newly Diagnosed Multiple Myeloma (NDMM) Patients Using Propensity Score Matching (PSM). <i>Blood</i> , 2018, 132, 3550-3550.	1.4	0
371	Prognostic Role of Neutrophil to Lymphocyte Ratio (NLR) in Myelofibrosis Patients Treated with Ruxolitinib: A Multi-Center Experience. <i>Blood</i> , 2018, 132, 4303-4303.	1.4	3
372	Once Weekly Versus Twice Weekly Carfilzomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma: A Pooled Analysis of Two Phase 1/2 Studies. <i>Blood</i> , 2018, 132, 1990-1990.	1.4	0
373	Alternative Overexpression of NRF2 or MYC Defines a Subgroup of Poor Prognosis Acute Myeloid Leukemia and Suggests a Novel Therapeutic Strategy By Combined Bromodomain Inhibition and Forced NRF2 Pathway Activation. <i>Blood</i> , 2018, 132, 2639-2639.	1.4	8
374	Long-Term Carfilzomib for High-Risk Patients with Newly Diagnosed Multiple Myeloma: A Pooled Analysis of Two Phase 1/2 Studies. <i>Blood</i> , 2018, 132, 3240-3240.	1.4	0
375	Transient Elastography Anticipates the Diagnosis of VOD/SOS after Adult Allogeneic Stem Cell Transplant: Results from a Prospective Study. <i>Blood</i> , 2018, 132, 2098-2098.	1.4	0
376	MDM2 and Aurora Kinase a Contribute to SETD2 Loss of Function in Advanced Systemic Mastocytosis: Implications for Pathogenesis and Treatment. <i>Blood</i> , 2018, 132, 1779-1779.	1.4	1
377	FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 3968-3975.	2.6	12
378	A Comparison of Different Staging Systems for Multiple Myeloma: Can the MRI Pattern Play a Prognostic Role?. <i>American Journal of Roentgenology</i> , 2017, 209, 152-158.	2.2	29

#	ARTICLE	IF	CITATIONS
379	The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. <i>Clinical Cancer Research</i> , 2017, 23, 3980-3993.	7.0	71
380	The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. <i>American Journal of Hematology</i> , 2017, 92, 797-805.	4.1	71
381	Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017, 28, iv52-iv61.	1.2	619
382	Retrospective Cohort Analysis of Liposomal Amphotericin B Nephrotoxicity in Patients with Hematological Malignancies. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	18
383	Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. <i>Leukemia</i> , 2017, 31, 2443-2448.	7.2	259
384	Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. <i>European Journal of Haematology</i> , 2017, 99, 199-206.	2.2	21
385	Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. <i>Haematologica</i> , 2017, 102, 1530-1536.	3.5	15
386	Ocular surface analysis in hematological patients before and after allogeneic hematopoietic stem cell transplantation: implication for daily clinical practice. <i>Eye</i> , 2017, 31, 1417-1426.	2.1	25
387	Addition of Lenalidomide to Azacitidine in Higher Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study. <i>Leukemia Research</i> , 2017, 55, S50-S51.	0.8	0
388	Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2017, 18, e206-e217.	10.7	394
389	Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents. <i>Haematologica</i> , 2017, 102, e104-e107.	3.5	13
390	Patient Characteristics, Skeletal Related Events (SRE) And Renal Impairment (RI) In Patients With Multiple Myeloma (MM): A Patient Chart Audit In EU5. <i>Value in Health</i> , 2017, 20, A413.	0.3	2
391	Impact of Arterial Thrombotic Events on the Outcome of Chronic Myeloid Leukemia Patients Treated with Nilotinib First-Line: A GIMEMA CML WP Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S313-S314.	0.4	1
392	Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma. <i>Annals of Hematology</i> , 2017, 96, 2071-2078.	1.8	4
393	Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. <i>Blood</i> , 2017, 130, 2610-2618.	1.4	90
394	Valosin-Containing Protein/p97 as a Novel Therapeutic Target in Acute Lymphoblastic Leukemia. <i>Neoplasia</i> , 2017, 19, 750-761.	5.3	20
395	Evolutionary Fitness of Relapsed Multiple Myeloma Patients Who Responded to Upfront Combination Therapy Including New Drugs. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e12.	0.4	0
396	Heavy+Light Chain and Free Light Chain Assays at Baseline and During Follow-up in EMN02/HO95 Multiple Myeloma Clinical Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e47.	0.4	0

#	ARTICLE	IF	CITATIONS
397	Final Survival Analysis From the FIRST Trial: Lenalidomide Plus Low-Dose Dexamethasone Until Progression (Rd Cont) v Melphalan, Prednisone and Thalidomide (MPT), and Rd for 18 Cycles (Rd18) for Transplant-Ineligible (TNE) Patients (Pts) With Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e63-e64.	0.4	4
398	Mutations in <i>JAK2</i> and <i>Calreticulin</i> genes are associated with specific alterations of the immune system in myelofibrosis. <i>Oncolmmunology</i> , 2017, 6, e1345402.	4.6	33
399	Toward a GEP-based PET in myeloma. <i>Blood</i> , 2017, 130, 2-3.	1.4	24
400	Radiologic findings of <i>Fusarium</i> pneumonia in neutropenic patients. <i>Mycoses</i> , 2017, 60, 73-78.	4.0	16
401	Second primary malignancies in multiple myeloma: an overview and IMWG consensus. <i>Annals of Oncology</i> , 2017, 28, 228-245.	1.2	102
402	A population-based study of chronic myeloid leukemia patients treated with imatinib in first line. <i>American Journal of Hematology</i> , 2017, 92, 82-87.	4.1	27
403	The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies - a European survey. <i>European Journal of Cancer Care</i> , 2017, 26, e12490.	1.5	24
404	Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. <i>American Journal of Hematology</i> , 2017, 92, 37-41.	4.1	62
405	Chromothripsis in acute myeloid leukemia: Biological features and impact on survival. <i>Leukemia</i> , 2017, , .	7.2	3
406	Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network. <i>Leukemia</i> , 2017, , .	7.2	11
407	Understanding Mortality In Multiple Myeloma (MM): Findings From An Observational Chart Review of Deceased Patients In The UK, France, Germany, Italy And Spain. <i>Value in Health</i> , 2017, 20, A420.	0.3	0
408	The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling. <i>Oncotarget</i> , 2017, 8, 2261-2274.	1.8	46
409	The More, The Better: "Do the Right Thing" For Natural Killer Immunotherapy in Acute Myeloid Leukemia. <i>Frontiers in Immunology</i> , 2017, 8, 1330.	4.8	21
410	ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells. <i>Frontiers in Immunology</i> , 2017, 8, 1918.	4.8	72
411	The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report. <i>BMC Cancer</i> , 2017, 17, 523.	2.6	2
412	The relevance of a low <i>JAK2</i> V617F allele burden in clinical practice: a monocentric study. <i>Oncotarget</i> , 2017, 8, 37239-37249.	1.8	18
413	Impact of Bortezomib- or Lenalidomide-Based Induction Treatment on High Risk Cytogenetic Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Enrolled in the Gimema-MM-03-05 and EMN01 Trials. <i>Blood</i> , 2017, 130, 744-744.	1.4	10
414	First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2017, 130, 99-99.	1.4	63

#	ARTICLE	IF	CITATIONS
415	Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: Planned interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8003-8003.	1.6	13
416	Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8006-8006.	1.6	18
417	Safety and efficacy of daratumumab-based regimens in elderly (≥75 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8033-8033.	1.6	3
418	Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells. <i>Oncotarget</i> , 2017, 8, 5895-5908.	1.8	45
419	Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy. <i>Oncotarget</i> , 2017, 8, 29906-29913.	1.8	22
420	Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. <i>Oncotarget</i> , 2017, 8, 79073-79086.	1.8	63
421	Chibby 1: a new component of β -catenin-signaling in chronic myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 88244-88250.	1.8	5
422	Abstract 3936: A branching evolution model at relapse characterizes multiple myeloma patients who responded to upfront combination therapy including new drugs. , 2017, , .		0
423	Abstract 1758: A more mature immunophenotypic makeup of multiple myeloma clone(s) at diagnosis correlates with a higher genomic instability. , 2017, , .		0
424	Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and Splenomegaly. <i>Mediators of Inflammation</i> , 2016, 2016, 1-7.	3.0	23
425	The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD). <i>Oncotarget</i> , 2016, 7, 9666-9679.	1.8	33
426	Multiple myeloma: practice patterns across Europe. <i>British Journal of Haematology</i> , 2016, 175, 66-76.	2.5	91
427	Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2016, 91, 617-622.	4.1	10
428	<sc>FGFR</sc>1 and <sc>KAT6A</sc> rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features. <i>American Journal of Hematology</i> , 2016, 91, E14-6.	4.1	4
429	Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years. <i>American Journal of Hematology</i> , 2016, 91, E267-72.	4.1	68
430	In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. <i>BMC Cancer</i> , 2016, 16, 572.	2.6	23
431	Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138 ⁺ CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis. <i>Leukemia</i> , 2016, 30, 1869-1876.	7.2	9
432	Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. <i>Drugs</i> , 2016, 76, 853-867.	10.9	34

#	ARTICLE	IF	CITATIONS
433	Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 374, 1621-1634.	27.0	861
434	Together for better?. <i>Blood</i> , 2016, 127, 375-376.	1.4	3
435	Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. <i>Blood</i> , 2016, 128, 497-503.	1.4	144
436	Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly. <i>British Journal of Haematology</i> , 2016, 174, 160-162.	2.5	7
437	Multiple myeloma: patient outcomes in real-world practice. <i>British Journal of Haematology</i> , 2016, 175, 252-264.	2.5	220
438	Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma. <i>Haematologica</i> , 2016, 101, 872-878.	3.5	19
439	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology</i> , The, 2016, 17, e328-e346.	10.7	1,866
440	Multiple myeloma: disease response assessment. <i>Expert Review of Hematology</i> , 2016, 9, 831-837.	2.2	8
441	Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology. <i>Journal of Nephrology</i> , 2016, 29, 735-746.	2.0	23
442	Inverse probability weighting to estimate causal effect of a singular phase in a multiphase randomized clinical trial for multiple myeloma. <i>BMC Medical Research Methodology</i> , 2016, 16, 150.	3.1	25
443	Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. <i>Haematologica</i> , 2016, 101, 1200-1207.	3.5	22
444	Complex chromosomal rearrangements leading to <i>MECOM</i> overexpression are recurrent in myeloid malignancies with various 3q abnormalities. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 375-388.	2.8	5
445	Improved Radiographic Imaging of Invasive Fungal Disease: The Cornerstone to Antifungal Stewardship in the Hematology Units?. <i>Current Fungal Infection Reports</i> , 2016, 10, 78-86.	2.6	6
446	Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. <i>Leukemia and Lymphoma</i> , 2016, 57, 2833-2838.	1.3	27
447	Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients. <i>Clinical Cancer Research</i> , 2016, 22, 1914-1921.	7.0	110
448	Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma. <i>Expert Review of Hematology</i> , 2016, 9, 315-323.	2.2	5
449	Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients. <i>Leukemia</i> , 2016, 30, 1615-1619.	7.2	16
450	Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens. <i>Leukemia and Lymphoma</i> , 2016, 57, 2058-2064.	1.3	12

#	ARTICLE	IF	CITATIONS
451	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. <i>Journal of Clinical Oncology</i> , 2016, 34, 1544-1557.	1.6	294
452	18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. <i>Leukemia</i> , 2016, 30, 417-422.	7.2	120
453	Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USE). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 414-421.	6.4	92
454	Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis. <i>Blood</i> , 2016, 128, 1128-1128.	1.4	4
455	Final Analysis of Overall Survival from the First Trial. <i>Blood</i> , 2016, 128, 241-241.	1.4	11
456	Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial). <i>Blood</i> , 2016, 128, 242-242.	1.4	26
457	Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2016, 128, 243-243.	1.4	3
458	Impact of Age on Efficacy, Safety, and Long-Term Outcome of Chronic Myeloid Leukemia (CML) Patients Treated in First-Line with Nilotinib: An Analysis of the Gimema CML Working Party. <i>Blood</i> , 2016, 128, 3068-3068.	1.4	1
459	Prognostic Value of BCR-ABL1 Transcript Type in Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. <i>Blood</i> , 2016, 128, 3070-3070.	1.4	10
460	Evaluation of Experimental Retreatment and Prolonged Therapy with Subcutaneous (SC) Bortezomib in Patients (Pts) with Multiple Myeloma in First or Second Relapse, a Randomized, Controlled, Phase 3 Study. <i>Blood</i> , 2016, 128, 3328-3328.	1.4	1
461	Efficacy and Safety of Ruxolitinib in Elderly Patients (> 75 years) with Myelofibrosis. <i>Blood</i> , 2016, 128, 4251-4251.	1.4	2
462	Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial). <i>Blood</i> , 2016, 128, 673-673.	1.4	29
463	Upfront Single Versus Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95) Tj ETQq1 1.0.7843136orgBT / O	1.4	13
464	Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8000-8000.	1.6	52
465	Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients. <i>Oncotarget</i> , 2016, 7, 21982-21990.	1.8	52
466	Crucial factors of the inflammatory microenvironment (IL-1 β /TNF- α /TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study. <i>Oncotarget</i> , 2016, 7, 43974-43988.	1.8	21
467	Abstract 90: A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia. <i>Cancer Research</i> , 2016, 76, 90-90.	0.9	1
468	Abstract 3582: Chromothripsis in AML patients: A new mechanism of cancer initiation and progression. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
469	Abstract 4077: Crucial factors of the inflammatory microenvironment (IL-1 ⁺ /TNF- ⁺ /TIMP-1) promote the selection of highly malignant hemopoietic clone of myelofibrosis. , 2016, , .		0
470	Abstract 3189: The alternate activation of hedgehog pathway, either in CD138+ or in CD138-CD19+ multiple myeloma primary cells, impacts on disease outcome. , 2016, , .		0
471	Abstract 5022: The selection of TP53 sub-clonal variants over time identifies MM patients with adverse clinical outcome. , 2016, , .		0
472	The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy. Blood, 2016, 128, 3097-3097.	1.4	0
473	A Branching Evolution Model at Relapse Characterizes Multiple Myeloma Patients Who Responded to up-Front Combination Therapy Including New Drugs. Blood, 2016, 128, 2080-2080.	1.4	1
474	Chemotherapy-Dependent ATP Release from Leukemia Dying Cells Induces Indoleamine 2,3-Dioxygenase 1 in Dendritic Cells. Blood, 2016, 128, 3711-3711.	1.4	0
475	Longer Time to Best Response and Depth of Response Are Associated with Improved Duration of Best Achieved Response and Progression-Free Survival (PFS): Post-Hoc Analysis of Phase 3 Tourmaline-MM1 Trial in Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2016, 128, 2134-2134.	1.4	0
476	Prospective Evaluation of 18F-FDG PET/CT As Predictor of Prognosis in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results from the Imaging Sus-Study of the EMN02/HO95 MM Randomized Phase III Trial. Blood, 2016, 128, 992-992.	1.4	0
477	Impact of Comorbidities and Body Mass Index in Myelofibrosis Patients Treated with Ruxolitinib: A Retrospective Analysis. Blood, 2016, 128, 5464-5464.	1.4	0
478	An Integrated Analysis of Cardio-Vascular Adverse Events of Carfilzomib, Cyclophosphamide and Dexamethasone in Elderly Newly Diagnosed Myeloma Patients Enrolled in 3 Phase I/II Trials. Blood, 2016, 128, 3336-3336.	1.4	0
479	Impact of Treatment Intensification According to Patient Prognosis: A Pooled Analysis of 3 Randomized Phase III Trials. Blood, 2016, 128, 995-995.	1.4	0
480	Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study. Blood, 2016, 128, 4414-4414.	1.4	0
481	Hevlyte and Freelite Tests in Newly Diagnosed Multiple Myeloma: Clinical Utility and Correlations with Clinical Features. Blood, 2016, 128, 5625-5625.	1.4	0
482	Bone Marrow Reticulin Fibrosis in 579 Patients with Polycythemia Vera and Essential Thrombocythemia: Effect on Clinical Outcome. Blood, 2016, 128, 3130-3130.	1.4	0
483	A Population-Based Study of Chronic Myeloid Leukemia Treated with Imatinib in First Line. Blood, 2016, 128, 3076-3076.	1.4	0
484	Prognostic Implication of Somatic Mutations By Next Generation Sequencing: An Analysis from the Mmrif Compass Study in Newly Diagnosed Multiple Myeloma Patients. Blood, 2016, 128, 2079-2079.	1.4	0
485	Signals of the Inflammatory Microenvironment Promote a Mutation-Associated Functional Dysregulation of the Circulating Megakaryocyte Progenitors of Myelofibrosis. Blood, 2016, 128, 3142-3142.	1.4	0
486	Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study. Blood, 2016, 128, 3169-3169.	1.4	6

#	ARTICLE	IF	CITATIONS
487	The Genomic and Transcriptomic Landscape of Systemic Mastocytosis. <i>Blood</i> , 2016, 128, 3136-3136.	1.4	1
488	Outcome of first salvage therapy for multiple myeloma (MM) in real-world clinical practice: Results from the third interim analysis of the multinational, observational, non-interventional EMMOS study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e274-e275.	0.4	0
489	Four phase 3 studies of the oral proteasome inhibitor (PI) ixazomib for multiple myeloma in the newly-diagnosed, relapsed/refractory, and maintenance settings: TOURMALINE-MM1, -MM2, -MM3, and -MM4. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e174.	0.4	4
490	Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study. <i>Stem Cell Research and Therapy</i> , 2015, 6, 64.	5.5	25
491	Human cord blood-derived platelet lysate enhances the therapeutic activity of adipose-derived mesenchymal stromal cells isolated from Crohn's disease patients in a mouse model of colitis. <i>Stem Cell Research and Therapy</i> , 2015, 6, 170.	5.5	26
492	Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment. <i>American Journal of Hematology</i> , 2015, 90, 647-652.	4.1	34
493	FP534 EXTRACORPOREAL TREATMENTS FOR LIGHT CHAIN REMOVAL IN MYELOMA-INDUCED CAST NEPHROPATHY. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii251-iii251.	0.7	0
494	14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β -catenin Antagonist chibby 1 in Chronic Myeloid Leukemia. <i>PLoS ONE</i> , 2015, 10, e0131074.	2.5	9
495	PGE ₂ -Induced IDO1 Inhibits the Capacity of Fully Mature DCs to Elicit an In Vitro Antileukemic Immune Response. <i>Journal of Immunology Research</i> , 2015, 2015, 1-10.	2.2	53
496	The Human Mesenchymal Stromal Cell-Derived Osteocyte Capacity to Modulate Dendritic Cell Functions Is Strictly Dependent on the Culture System. <i>Journal of Immunology Research</i> , 2015, 2015, 1-10.	2.2	6
497	Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms. <i>Annals of Hematology</i> , 2015, 94, 1585-1587.	1.8	13
498	Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. <i>Haematologica</i> , 2015, 100, 1327-1333.	3.5	68
499	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015, 26, 185-192.	1.2	72
500	Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement. <i>Journal of Clinical Oncology</i> , 2015, 33, 657-664.	1.6	330
501	Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 673-678.	2.4	21
502	Bendamustine for the treatment of multiple myeloma in first-line and relapsed/refractory settings: a review of clinical trial data. <i>Leukemia and Lymphoma</i> , 2015, 56, 559-567.	1.3	12
503	The Role of Positron Emission Tomography with 18F-Fluorodeoxyglucose Integrated with Computed Tomography in the Evaluation of Patients with Multiple Myeloma Undergoing Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1068-1073.	2.0	46
504	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2015, 33, 2863-2869.	1.6	1,525

#	ARTICLE	IF	CITATIONS
505	High Resolution Computed Tomography Angiography Improves the Radiographic Diagnosis of Invasive Mold Disease in Patients With Hematological Malignancies. <i>Clinical Infectious Diseases</i> , 2015, 60, 1603-1610.	5.8	83
506	Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. <i>Leukemia</i> , 2015, 29, 1344-1349.	7.2	62
507	PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015, 21, 4384-4390.	7.0	140
508	Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. <i>Haematologica</i> , 2015, 100, 1146-1150.	3.5	39
509	Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. <i>Haematologica</i> , 2015, 100, 1334-1339.	3.5	44
510	Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. <i>Leukemia</i> , 2015, 29, 1823-1831.	7.2	77
511	European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. <i>Haematologica</i> , 2015, 100, 1254-1266.	3.5	289
512	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2039-2051.	2.0	146
513	Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. <i>Leukemia</i> , 2015, 29, 2429-2431.	7.2	57
514	The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling. <i>Experimental Hematology</i> , 2015, 43, 974-985.e1.	0.4	24
515	Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3459-3466.	1.6	138
516	Rare High Risk IgH Translocations in Newly Diagnosed Multiple Myeloma (MM): Cytogenetic Characterization and Relevance on Prognosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e46-e47.	0.4	0
517	Outcomes of Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI) Treated With Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in the Phase 3b STRATUS(TM) Trial (MM-010). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e266.	0.4	0
518	Two randomized open-label studies of daratumumab (DARA) plus standard of care treatment versus standard of care alone in patients with previously untreated multiple myeloma (MM) ineligible for high-dose therapy: 54767414MMY3007 (Alcyone) and 54767414MMY3008 (Maia). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e294-e295.	0.4	1
519	Adverse Event (AE) Management With Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in the STRATUS(TM) Trial: A Phase 3b Study Evaluating Safety and Efficacy in Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e264.	0.4	0
520	Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma. <i>Translational Research</i> , 2015, 165, 641-650.	5.0	47
521	Risk Factors for Infections in Myelofibrosis: Role of Disease Status and Treatment. A Study on 507 Patients. <i>Blood</i> , 2015, 126, 1606-1606.	1.4	2
522	Long-Term Outcome to First-Line Imatinib according to 2013 European LeukemiaNet Response Criteria: a GIMEMA CML WP Analysis. <i>Blood</i> , 2015, 126, 2792-2792.	1.4	2

#	ARTICLE	IF	CITATIONS
523	Demographics, Baseline Characteristics, and Disease Symptom Burden in RESPONSE-2: A Randomized, Phase 3 Study of Ruxolitinib in Polycythemia Vera Patients (pts) Who Are Resistant to or Intolerant of Hydroxyurea (HU). <i>Blood</i> , 2015, 126, 2807-2807.	1.4	2
524	BCR-ABL Mutations in Chronic Myeloid Leukemia (CML) Patients (pts) with Failure and Warning to First- and Second-Line Tyrosine Kinase Inhibitor (TKI) Therapy: What Is the Advantage of Next-Generation Sequencing (NGS) over Conventional Sequencing?. <i>Blood</i> , 2015, 126, 346-346.	1.4	12
525	Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis. <i>Blood</i> , 2015, 126, 4085-4085.	1.4	2
526	An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2015, 126, 4225-4225.	1.4	3
527	Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537). <i>Blood</i> , 2015, 126, 727-727.	1.4	32
528	Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial. <i>Blood</i> , 2015, 126, 730-730.	1.4	15
529	Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients. <i>Oncotarget</i> , 2015, 6, 31284-31294.	1.8	18
530	Abstract 4248: A long tail of sub-clonal TP53 mutations emerged by ultra-deep sequencing of newly diagnosed multiple myeloma (MM). , 2015, , .		0
531	Abstract 4848: SNP array reveals a new deletion of JAK2 in AML patients. , 2015, , .		0
532	Abstract 4835: A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1. , 2015, , .		0
533	Abstract 1521: High-throughput molecular profiling of Multiple Myeloma clonotypic CD19+ B cells highlights pathways potentially involved in the disease endurance. , 2015, , .		0
534	Abstract 3957: Integrated molecular characterization of mast cell leukemia reveals recurrent inactivation of the SETD2 tumor suppressor gene. , 2015, , .		0
535	Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients. <i>Blood</i> , 2015, 126, 3198-3198.	1.4	0
536	Genomic-Wide Analysis By High Resolution SNP Array Identifies Novel Genomic Alteration in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2600-2600.	1.4	0
537	Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3837-3837.	1.4	0
538	The Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) Regulates the Function and Migration of Leukemic Blasts through CD63/PI3K/AKT/P21 Axis. <i>Blood</i> , 2015, 126, 2394-2394.	1.4	1
539	Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) in Italy: A Subanalysis of the Stratus Trial (MM-010). <i>Blood</i> , 2015, 126, 5376-5376.	1.4	0
540	JAK2V617F-Positive Patients with Essential Thrombocythemia or Early Primary Myelofibrosis: The Impact of Histological Diagnosis on Outcome. <i>Blood</i> , 2015, 126, 1614-1614.	1.4	0

#	ARTICLE	IF	CITATIONS
541	P2X7 Receptor Activation By ATP As Target of Novel Therapies in Acute Myeloid Leukemia. Blood, 2015, 126, 3684-3684.	1.4	0
542	Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood, 2015, 126, 2513-2513.	1.4	0
543	Analysis of Patient (Pt) Outcomes By Prior Treatment and Depth of Response in Stratus (MM-010), a Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2015, 126, 1834-1834.	1.4	0
544	18F-Fluorothymidine Positron Emission Tomography in Patients with Suspect Lymphoma Relapse. Blood, 2015, 126, 5009-5009.	1.4	0
545	Long-Term Clinical Outcomes of Allogeneic Stem Cell Transplantation in Multiple Myeloma. Blood, 2015, 126, 1968-1968.	1.4	0
546	Clinical Relevance of Low Burden BCR-ABL1 Mutations Detectable By Amplicon Deep Sequencing (DS) in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (pts): The Type of Mutation Matters. Blood, 2015, 126, 2489-2489.	1.4	2
547	Association of Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes. Final Results of a Randomized Phase II Multicenter Study. Blood, 2015, 126, 2871-2871.	1.4	2
548	Crucial Factors of the Inflammatory Microenvironment (IL-1 beta/TNF-alpha/TIMP-1) Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating the in Vitro Survival/Proliferation/Migration of Circulating CD34+ stem/Progenitor Cells. Blood, 2015, 126, 4094-4094.	1.4	0
549	The Induction of Inhibitory Pathways in Dendritic Cells May Hamper the Efficient Activation of Anti-Leukemia T Cells within Chemotherapy-Induced Immunogenic Cell Death. Blood, 2015, 126, 1019-1019.	1.4	0
550	A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium. Blood, 2015, 126, 3840-3840.	1.4	0
551	Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients. Blood, 2015, 126, 927-927.	1.4	2
552	Aurora Kinase a: A New Component of Imatinib Resistance in Chronic Myeloid Leukemia. Blood, 2015, 126, 1573-1573.	1.4	0
553	The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia. Blood, 2015, 126, 2478-2478.	1.4	0
554	An Amplicon-Targeted Ultra-Deep Sequencing Approach Reveals the Presence at the Onset of Multiple Myeloma and the Selection over Time of TP53 Sub-Clonal Variants, Which Adversely Influence Patients' Overall Survival. Blood, 2015, 126, 24-24.	1.4	0
555	Upregulation of Indoleamine 2,3-Dioxygenase Enzymes in Leukemic Mesenchymal Stromal Cells (MSCs) Can Influence MSC/Acute Myeloid Leukemia Cell Cross Talk. Blood, 2015, 126, 1191-1191.	1.4	0
556	Long-Term Responders after Brentuximab Vedotin: Experience on 57 Patients with Relapsed and Refractory Hodgkin and Anaplastic Large Cell Lymphoma. Blood, 2015, 126, 2725-2725.	1.4	1
557	Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. Oncotarget, 2014, 5, 1779-1792.	1.8	53
558	Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia, 2014, 28, 1573-1585.	7.2	108

#	ARTICLE	IF	CITATIONS
559	The impact of long-term lenalidomide exposure on the cellular composition of bone marrow. <i>Leukemia and Lymphoma</i> , 2014, 55, 2665-2668.	1.3	2
560	Maintenance therapy in newly diagnosed multiple myeloma: current recommendations. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 581-594.	2.4	5
561	Glutathione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation. <i>Haematologica</i> , 2014, 99, 172-179.	3.5	31
562	IMWG consensus on risk stratification in multiple myeloma. <i>Leukemia</i> , 2014, 28, 269-277.	7.2	500
563	European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. <i>Haematologica</i> , 2014, 99, 232-242.	3.5	185
564	Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes. <i>Annals of Hematology</i> , 2014, 93, 123-128.	1.8	15
565	Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. <i>Leukemia</i> , 2014, 28, 1705-1715.	7.2	207
566	Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. <i>American Journal of Hematology</i> , 2014, 89, 355-362.	4.1	24
567	Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. <i>Blood</i> , 2014, 123, 3414-3419.	1.4	68
568	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 333-342.	10.7	256
569	International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 587-600.	1.6	330
570	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology</i> , The, 2014, 15, e538-e548.	10.7	3,343
571	HIF-1 α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment. <i>Experimental Cell Research</i> , 2014, 328, 444-455.	2.6	27
572	The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. <i>British Journal of Haematology</i> , 2014, 165, 441-454.	2.5	91
573	European Perspective on Multiple Myeloma Treatment Strategies in 2014. <i>Oncologist</i> , 2014, 19, 829-844.	3.7	90
574	Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. <i>American Journal of Hematology</i> , 2014, 89, 1085-1091.	4.1	45
575	Initial treatment of transplant-eligible patients in multiple myeloma. <i>Expert Review of Hematology</i> , 2014, 7, 43-53.	2.2	14
576	Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival. <i>Journal of Clinical Oncology</i> , 2014, 32, 634-640.	1.6	198

#	ARTICLE	IF	CITATIONS
577	Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. <i>Cancer</i> , 2014, 120, 1002-1009.	4.1	116
578	First-Line Treatment of Newly Diagnosed Elderly Patients with Chronic Myeloid Leukemia: Current and Emerging Strategies. <i>Drugs</i> , 2014, 74, 627-643.	10.9	20
579	Autologous Transplantation and Maintenance Therapy in Multiple Myeloma. <i>New England Journal of Medicine</i> , 2014, 371, 895-905.	27.0	683
580	Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma. <i>New England Journal of Medicine</i> , 2014, 371, 906-917.	27.0	697
581	Positron Emission Tomography With Computed Tomography-Based Diagnosis of Massive Extramedullary Progression in a Patient With High-Risk Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e101-e104.	0.4	10
582	Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progression-Related Death. <i>Journal of Clinical Oncology</i> , 2014, 32, 2173-2180.	1.6	150
583	Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma. <i>Haematologica</i> , 2014, 99, e242-e243.	3.5	6
584	Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and High-Dose Melphalan (HDM) As First Line Treatment for Multiple Myeloma (MM) Is Associated with a Lower Rate of Second Primary Malignancies (SPMs) Compared to TD Plus HDM. <i>Blood</i> , 2014, 124, 1182-1182.	1.4	2
585	Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia. <i>Blood</i> , 2014, 124, 1881-1881.	1.4	2
586	Superior PFS2 with VTD Vs TD for Newly Diagnosed, Transplant Eligible, Multiple Myeloma (MM) Patients: Updated Analysis of Gimema MMY-3006 Study. <i>Blood</i> , 2014, 124, 196-196.	1.4	11
587	Superior Efficacy of VTD over VCD As Induction Therapy for Autotransplantation-Eligible, Newly Diagnosed, Myeloma Patients. <i>Blood</i> , 2014, 124, 197-197.	1.4	5
588	Rare Igh Translocations in Newly Diagnosed Multiple Myeloma (MM) Patients: Cytogenetic Characterization and Relevance on Prognosis. <i>Blood</i> , 2014, 124, 2042-2042.	1.4	1
589	The Presence of FDG PET/CT Focal, Not Osteolytic, Lesion(s) Identifies a Sub-Group of Patients with Smoldering Multiple Myeloma with High-Risk of Progression into Symptomatic Disease. <i>Blood</i> , 2014, 124, 3371-3371.	1.4	3
590	Addition of Lenalidomide (LEN) to Azacitidine (AZA) (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes (MDS): A Randomized Phase II Multicenter Study. <i>Blood</i> , 2014, 124, 4648-4648.	1.4	3
591	Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma and Renal Impairment: Analysis of Patients from the Phase 3b Stratus Trial (MM-010). <i>Blood</i> , 2014, 124, 4755-4755.	1.4	10
592	Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome. <i>Blood</i> , 2014, 124, 484-484.	1.4	3
593	Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 80-80.	1.4	2
594	The STRATUS trial (MM-010): A single-arm phase 3b study of pomalidomide plus low-dose dexamethasone (POM + LoDEX) in refractory or relapsed and refractory multiple myeloma. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS8625-TPS8625.	1.6	2

#	ARTICLE	IF	CITATIONS
595	Abstract 3608: HIF-1 α inhibition blocks the cross talk between multiple myeloma plasmacells and tumour microenvironment. , 2014, , .		0
596	Abstract 3884: Gene expression profiling and copy number alterations of circulating clonotypic B cells of multiple myeloma newly diagnosed patients reveals pathways potentially involved in the development and in the disease persistence. , 2014, , .		0
597	Abstract 5595: Impact of p53 impaired function on outcomes of multiple myeloma patients carrying deleted TP53 and/or amplified MDM4. , 2014, , .		0
598	Deep Molecular Response to Nilotinib As First-Line Treatment of BCR-ABL+ CML in Early Chronic Phase: A Phase 3b Multicenter Study of the Gimema CML Working Party. Blood, 2014, 124, 4532-4532.	1.4	0
599	Outcomes for Older Patients in Stratus (MM-010), a Single-Arm, and Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma. Blood, 2014, 124, 4770-4770.	1.4	1
600	Backtracking BCR-ABL1 Mutants in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Relapsing on Tyrosine Kinase Inhibitors with Deep Sequencing: Implications for Routine Mutation Testing. Blood, 2014, 124, 2259-2259.	1.4	0
601	High-Throughput Molecular Profiling of Multiple Myeloma (MM) Clonotypic CD19+ B Cells Highlights Pathways Potentially Involved in the Disease Endurance. Blood, 2014, 124, 2054-2054.	1.4	0
602	Virtual Karyotype Reconstruction By SNPs Array of Newly Diagnosed Multiple Myeloma (MM) Patients Enrolled in the EMNO2 Clinical Trial. Blood, 2014, 124, 2033-2033.	1.4	0
603	Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis. Blood, 2014, 124, 1856-1856.	1.4	0
604	Mutations and Long-Term Outcome of 217 Young Patients with Essential Thrombocythemia or Early Primary Myelofibrosis. Blood, 2014, 124, 3190-3190.	1.4	0
605	In Chronic Myeloid Leukemia Patients on 2nd-Line Tyrosine Kinase Inhibitor Therapy, Deep Sequencing at the Time of Warning May Allow Sensitive Detection of Emerging BCR-ABL1 Mutants. Blood, 2014, 124, 815-815.	1.4	0
606	Five-Year Outcome of 215 Newly Diagnosed Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib-Based Regimens: A Gimema CML Working Party Analysis. Blood, 2014, 124, 3141-3141.	1.4	10
607	Donor Natural Killer (NK) Alloreactivity Predicts Long-Term Relapse-Free Survival in Acute Myeloid Leukemia Patients Undergoing Immunotherapy with NK Cells. Blood, 2014, 124, 624-624.	1.4	1
608	A Long Tail of Sub-Clonal TP53 Mutations Emerged By Ultra-Deep Sequencing of Newly Diagnosed Multiple Myeloma (MM). Blood, 2014, 124, 3400-3400.	1.4	0
609	Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide+dexamethasone incorporated into double autologous transplantation. Annals of Hematology, 2013, 92, 1271-1280.	1.8	10
610	Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors. Expert Review of Hematology, 2013, 6, 563-574.	2.2	24
611	International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma-Related Bone Disease. Journal of Clinical Oncology, 2013, 31, 2347-2357.	1.6	307
612	Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood, 2013, 122, 1634-1648.	1.4	152

#	ARTICLE	IF	CITATIONS
613	Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials. <i>Journal of Clinical Oncology</i> , 2013, 31, 3279-3287.	1.6	238
614	Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2013, 14, 1055-1066.	10.7	710
615	Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1975-1981.	1.3	16
616	Una valutazione economica di due sequenze terapeutiche nel trattamento del mieloma multiplo ricaduto e/o refrattario. <i>Pharmacoeconomics Italian Research Articles</i> , 2013, 15, 1-8.	0.2	0
617	Role of Consolidation Therapy in Transplant Eligible Multiple Myeloma Patients. <i>Seminars in Oncology</i> , 2013, 40, 610-617.	2.2	10
618	Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. <i>Leukemia</i> , 2013, 27, 780-791.	7.2	294
619	Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. <i>Leukemia</i> , 2013, 27, 711-717.	7.2	174
620	Update on the treatment of Ph-negative myeloproliferative neoplasms. <i>International Journal of Hematologic Oncology</i> , 2013, 2, 251-262.	1.6	1
621	Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy. <i>British Journal of Haematology</i> , 2013, 161, 291-294.	2.5	4
622	Cap dependent translation contributes to resistance of myeloma cells to bortezomib. <i>Translation</i> , 2013, 1, e27245.	2.9	3
623	Cost of Illness in Patients with Multiple Myeloma in Italy: The CoMiM Study. <i>Tumori</i> , 2013, 99, e193-e202.	1.1	14
624	The Value of 18F-FDG PET/CT after Autologous Stem Cell Transplantation (ASCT) in Patients Affected by Multiple Myeloma (MM). <i>Clinical Nuclear Medicine</i> , 2013, 38, e74-e79.	1.3	65
625	Prognostic Impact Of Serum Free Light Chain (sFLC) Assay In Newly Diagnosed Multiple Myeloma (MM) Treated With Bortezomib. <i>Blood</i> , 2013, 122, 1859-1859.	1.4	1
626	PET/CT Is a Useful Tool For Both Refining The Definition Of Complete Response (CR) In Multiple Myeloma (MM) and Detecting Otherwise Unrevealed Progression During The Follow-Up Of The Disease: A Single Centre Experience On 282 Patients. <i>Blood</i> , 2013, 122, 1936-1936.	1.4	2
627	Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus) Tj ETQq1 1 0.784314 rgBT /Ov (Pts) Ineligible For Stem Cell Transplantation (SCT). <i>Blood</i> , 2013, 122, 2-2.	1.4	39
628	Persistent Improvement In Clinical Outcomes With Bortezomib-Thalidomide-Dexamethasone Vs Thalidomide-Dexamethasone Incorporated Into Double Autologous Transplantation For Multiple Myeloma: An Updated Analysis Of Phase 3 Gimema-MMY-3006 Study. <i>Blood</i> , 2013, 122, 2090-2090.	1.4	6
629	Frontline Treatment With Imatinib Mesylate in Chronic Myeloid Leukemia Patients in Early Chronic Phase: a Very Long-Term Analysis by the GIMEMA CML Working Party. <i>Blood</i> , 2013, 122, 258-258.	1.4	2
630	MM-003 Phase 3 Study Of Pomalidomide In Combination With Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM): POM + Lodex Is Beneficial For Elderly Patients (> 65 Years of Age). <i>Blood</i> , 2013, 122, 3198-3198.	1.4	2

#	ARTICLE	IF	CITATIONS
631	Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy. <i>Blood</i> , 2013, 122, 380-380.	1.4	2
632	Final Analysis, Cytogenetics, Long-Term Treatment, and Long-Term Survival In MM-003, A Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2013, 122, 408-408.	1.4	10
633	Patient Outcomes By Prior Therapies and Depth Of Response: Analysis Of MM-003, a Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2013, 122, 686-686.	1.4	2
634	Serum Free Light Chain Escape In Progression and Treatment Resistance In Multiple Myeloma: A Marker For The Impact Of Intra-Clonal Heterogeneity. <i>Blood</i> , 2013, 122, 752-752.	1.4	1
635	Double Vs Single Autologous Stem Cell Transplantation After Bortezomib-Based Induction Regimens For Multiple Myeloma: An Integrated Analysis Of Patient-Level Data From Phase European III Studies. <i>Blood</i> , 2013, 122, 767-767.	1.4	56
636	Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8517-8517.	1.6	6
637	A Risk Prediction Score for Invasive Mold Disease in Patients with Hematological Malignancies. <i>PLoS ONE</i> , 2013, 8, e75531.	2.5	51
638	Abstract 3749: Genomic characterization of the putative myeloma stem cells clone reveals alterations possibly correlated with the origin of disease.. , 2013, , .		0
639	Abstract 3415: SIRT regulates the molecular interaction between c-MYC and HIF-1 α in multiple myeloma.. , 2013, , .		0
640	Abstract 4700: Clinical outcome of T-acute lymphoblastic leukemia/lymphoma (T-ALL/T-LBL): the Bologna experience.. , 2013, , .		0
641	Abstract 4051: Loss of nuclear beta catenin, following chibby enforced expression, activates endoplasmic reticulum stress in cells expressing the BCR-ABL1 fusion gene of chronic myeloid leukemia.. , 2013, , .		0
642	The e13a2 BCR-ABL1 Fusion Transcript Is a Candidate Adverse Prognostic Factor In Chronic Myeloid Leukemia Patients Treated Frontline With Imatinib Mesylate. <i>Blood</i> , 2013, 122, 1486-1486.	1.4	0
643	4-Year Outcome Of 215 Patients With Newly Diagnosed Chronic Myeloid Leukemia (CML) Treated Frontline With Nilotinib In Investigator-Sponsored Studies. A Report From The Gimema CML Working Party. <i>Blood</i> , 2013, 122, 4000-4000.	1.4	0
644	Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4. <i>Blood</i> , 2013, 122, 1855-1855.	1.4	0
645	Single-Cell Genetic Analysis Reveals The Genetic Composition Of Founder Clones, Phylogenetic Patterns Of Branching and Parallel Evolution, and Clonal Fluctuations Following Patient Treatment In Multiple Myeloma. <i>Blood</i> , 2013, 122, 398-398.	1.4	0
646	Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003). <i>Blood</i> , 2013, 122, 3185-3185.	1.4	0
647	Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing Of The BCR-ABL Kinase Domain. <i>Blood</i> , 2013, 122, 3986-3986.	1.4	0
648	Newly Diagnosed Multiple Myeloma (MM) Patients Treated With Lenalidomide Induction and Maintenance Show a Low Incidence Of Second Primary Malignancies (SPMs). <i>Blood</i> , 2013, 122, 2074-2074.	1.4	2

#	ARTICLE	IF	CITATIONS
649	Cost of illness in patients with multiple myeloma in Italy: the CoMiM study. <i>Tumori</i> , 2013, 99, e193-202.	1.1	8
650	Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. <i>Bone Marrow Transplantation</i> , 2012, 47, 1248-1249.	2.4	6
651	European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses. <i>Oncologist</i> , 2012, 17, 592-606.	3.7	48
652	IMWG consensus on maintenance therapy in multiple myeloma. <i>Blood</i> , 2012, 119, 3003-3015.	1.4	178
653	Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. <i>Blood</i> , 2012, 119, 933-939.	1.4	260
654	Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2012, 120, 9-19.	1.4	305
655	The role of imaging techniques in the management of multiple myeloma. <i>British Journal of Haematology</i> , 2012, 159, 499-513.	2.5	108
656	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	7.2	664
657	Myeloma Genetics International Consortium. <i>Leukemia and Lymphoma</i> , 2012, 53, 796-800.	1.3	7
658	Contrast enhanced MRI and 18F-FDG PET-CT in the assessment of multiple myeloma: A comparison of results in different phases of the disease. <i>European Journal of Radiology</i> , 2012, 81, 4013-4018.	2.6	97
659	Proteasome inhibitors in multiple myeloma: 10 years later. <i>Blood</i> , 2012, 120, 947-959.	1.4	438
660	Management of treatment-emergent peripheral neuropathy in multiple myeloma. <i>Leukemia</i> , 2012, 26, 595-608.	7.2	217
661	Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2012, 366, 1759-1769.	27.0	692
662	SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. <i>Annals of Hematology</i> , 2012, 91, 875-888.	1.8	28
663	Primary plasma cell leukemia in the era of new drugs: Has something changed?. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 141-149.	4.4	18
664	Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective survey of 50 patients. <i>Cancer</i> , 2012, 118, 1574-1584.	4.1	102
665	Long-term results of thalidomide and dexamethasone (thal+dex) as therapy of first relapse in multiple myeloma. <i>Annals of Hematology</i> , 2012, 91, 419-426.	1.8	11
666	Bortezomib-Thalidomide-Dexamethasone Incorporated Into Autotransplantation Is Associated with More Favorable Outcomes After Relapse in Comparison with Thalidomide-Dexamethasone Plus Autotransplantation in Multiple Myeloma. <i>Blood</i> , 2012, 120, 4210-4210.	1.4	1

#	ARTICLE	IF	CITATIONS
667	Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies. <i>Blood</i> , 2012, 120, 749-749.	1.4	8
668	Abstract 1873: Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplifiedMDM4and/or deletedp53. , 2012, , .		0
669	The Poor Outcome of Multiple Myeloma (MM) Patients Carrying At Diagnosis Deleted TP53 and or Amplified MDM4 Might Be Related to the Deregulation of Genes Involved in Cell Cycle Control and DNA Damage Repair. <i>Blood</i> , 2012, 120, 1810-1810.	1.4	2
670	The Impact of Thalidomide Maintenance Therapy Varies Dependent Upon Biological Risk Grouping. <i>Blood</i> , 2012, 120, 199-199.	1.4	7
671	Ten Year-Long Term Survival After up-Front Autologous Stem Cell Transplantation in Multiple Myeloma: Results From Two Prospective Clinical Trials. <i>Blood</i> , 2012, 120, 594-594.	1.4	0
672	SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1 α in Multiple Myeloma. <i>Blood</i> , 2012, 120, 574-574.	1.4	0
673	Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 986-993.	1.6	302
674	Treatment of relapsed and refractory multiple myeloma in the era of novel agents. <i>Cancer Treatment Reviews</i> , 2011, 37, 266-283.	7.7	66
675	Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. <i>Blood</i> , 2011, 117, 4696-4700.	1.4	285
676	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. <i>Blood</i> , 2011, 117, 6063-6073.	1.4	282
677	Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). <i>Blood</i> , 2011, 118, 4519-4529.	1.4	309
678	Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. <i>Blood</i> , 2011, 118, 5989-5995.	1.4	445
679	A third-generation IMiD for MM. <i>Blood</i> , 2011, 118, 2931-2932.	1.4	12
680	Multiple Myeloma, Venous Thromboembolism, and Treatment-Related Risk of Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 209-219.	2.7	78
681	Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. <i>Blood</i> , 2011, 118, 5759-5766.	1.4	34
682	Patient with ataxia telangiectasia who developed acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2011, 52, 1818-1820.	1.3	9
683	Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective. <i>Oncologist</i> , 2011, 16, 388-403.	3.7	26
684	Superior Complete Response Rate (CR) and Progression-Free Survival (PFS) with Bortezomib-Thalidomide-Dexamethasone (VTD) Versus Thalidomide-Dexamethasone (TD) As Consolidation Therapy After Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 1871-1871.	1.4	4

#	ARTICLE	IF	CITATIONS
685	HIF 1 Alpha: A Suitable Target for Multiple Myeloma. <i>Blood</i> , 2011, 118, 2901-2901.	1.4	2
686	Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients <65 Years: Results of a Randomized Phase III Study. <i>Blood</i> , 2011, 118, 3069-3069.	1.4	11
687	Autologous Peripheral Blood Stem-Cell (PBSC) Collection Is Not Impaired by Bortezomib-Thalidomide-Dexamethasone (VTD) Induction Therapy in Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 317-317.	1.4	3
688	High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53. <i>Blood</i> , 2011, 118, 3935-3935.	1.4	1
689	A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65-75 Yrs Enrolled in MM-015. <i>Blood</i> , 2011, 118, 475-475.	1.4	12
690	Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial. <i>Blood</i> , 2011, 118, 480-480.	1.4	21
691	Abstract B53: Evaluation of HIF-1 α mRNA inhibitor as antimultiple myeloma agent. , 2011, , .		0
692	Bortezomib- and Thalidomide-Induced Peripheral Neuropathy (PN) in Multiple Myeloma (MM): Clinical and Molecular Analysis of 474 Patients Treated with Thalidomide-Dexamethasone (TD) or Bortezomib-TD (VTD). <i>Blood</i> , 2011, 118, 1821-1821.	1.4	1
693	Post-Approval Safety Study (PASS) of Lenalidomide Compared with Other Treatments in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2011, 118, 1867-1867.	1.4	0
694	Conventionally-Defined and PET/CT-Defined Complete Response (CR) to Novel Agent-Based Induction Therapy and Autologous Stem-Cell Transplantation (ASCT) In Multiple Myeloma (MM): A Prospective Study of Clinical and Prognostic Implications. <i>Blood</i> , 2011, 118, 826-826.	1.4	0
695	A Score Model for Predicting Unsuccessful or Sub-Optimal Peripheral Blood Stem Cell Collections in Multiple Myeloma Based on a Retrospective Analysis of 1,039 Patients Receiving Novel Agents As Induction Therapy and Cyclophosphamide Plus G-CSF As Mobilizing Regimen. <i>Blood</i> , 2011, 118, 4044-4044.	1.4	0
696	A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 805-805.	1.4	0
697	How I treat elderly patients with myeloma. <i>Blood</i> , 2010, 116, 2215-2223.	1.4	39
698	Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. <i>Blood</i> , 2010, 116, 3743-3750.	1.4	101
699	Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. <i>Blood</i> , 2010, 116, 4745-4753.	1.4	361
700	Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. <i>European Journal of Haematology</i> , 2010, 84, 223-228.	2.2	77
701	Thalidomide-dexamethasone as upfront therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. <i>European Journal of Haematology</i> , 2010, 84, 484-492.	2.2	31
702	Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2010, 28, 1599-1605.	1.6	142

#	ARTICLE	IF	CITATIONS
703	Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective. <i>Oncologist</i> , 2010, 15, 6-25.	3.7	85
704	European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. <i>Leukemia and Lymphoma</i> , 2010, 51, 2006-2011.	1.3	14
705	Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2010, 28, 4976-4984.	1.6	358
706	Thalidomide-Dexamethasone as Induction Therapy before Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma and Renal Insufficiency. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1115-1121.	2.0	33
707	Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. <i>Lancet</i> , The, 2010, 376, 2075-2085.	13.7	770
708	Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. <i>Leukemia and Lymphoma</i> , 2010, 51, 1424-1443.	1.3	49
709	Prognostic Impact of Cytogenetic Abnormalities On Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated with Thalidomide-Dexamethasone Incorporated Into Double Autologous Stem-Cell Transplantation: An Analysis of 593 Patients. <i>Blood</i> , 2010, 116, 3562-3562.	1.4	6
710	Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Induction and Consolidation Therapy Before and After Double Autologous Transplantation In Newly Diagnosed Multiple Myeloma: Results From a Randomized Phase 3 Study. <i>Blood</i> , 2010, 116, 42-42.	1.4	6
711	Bortezomib-Based Induction Treatments Improve Outcomes of Newly Diagnosed Multiple Myeloma Patients with High-Risk Cytogenetic Abnormalities. <i>Blood</i> , 2010, 116, 781-781.	1.4	6
712	Molecular Remission After Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Consolidation Therapy Following Double Autologous Transplantation for Multiple Myeloma: Results of a Qualitative and Quantitative Analysis. <i>Blood</i> , 2010, 116, 861-861.	1.4	11
713	Prognostic Relevance of 18F-FDG PET/CT In Newly Diagnosed Multiple Myeloma Patients Treated with up-Front Autologous Transplantation: A Prospective Study. <i>Blood</i> , 2010, 116, 369-369.	1.4	1
714	Thalidomide Maintenance in Multiple Myeloma: Certainties and Controversies. <i>Journal of Clinical Oncology</i> , 2009, 27, e186-e187.	1.6	12
715	Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison With Double Autotransplantation for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5001-5007.	1.6	46
716	The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. <i>Annals of Oncology</i> , 2009, 20, 1303-1317.	1.2	201
717	Systemic Cardiac Amyloidoses. <i>Circulation</i> , 2009, 120, 1203-1212.	1.6	622
718	Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. <i>European Journal of Haematology</i> , 2009, 82, 93-105.	2.2	21
719	International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. <i>Leukemia</i> , 2009, 23, 215-224.	7.2	686
720	International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. <i>Leukemia</i> , 2009, 23, 1716-1730.	7.2	136

#	ARTICLE	IF	CITATIONS
721	International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). <i>Leukemia</i> , 2009, 23, 1904-1912.	7.2	207
722	Ascorbic acid inhibits antitumor activity of bortezomib in vivo. <i>Leukemia</i> , 2009, 23, 1679-1686.	7.2	102
723	Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. <i>Blood</i> , 2009, 114, 1729-1735.	1.4	203
724	The Activity of Spanish and Italian Myeloma Groups. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S36-S39.	1.4	0
725	Single or Double Autologous Stem Cell Transplantation Before and After the Era of Novel Agents. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S51-S52.	1.4	1
726	PCN49 COSTS AND QUALITY OF LIFE OF MULTIPLE MYELOMA (MM) IN ITALY: THE CO.MI.M. STUDY. <i>Value in Health</i> , 2009, 12, A265.	0.3	0
727	First-Line Treatment of Multiple Myeloma in Elderly Patients: the GIMEMA (Gruppo Italiano Malattie) Tj ETQq1 1 0.784314 rgBT /Overl 10, 906-922.	2.1	9
728	Clinical Outcomes According to Genomic Abnormalities in 566 Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens.. <i>Blood</i> , 2009, 114, 1868-1868.	1.4	2
729	A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD.. <i>Blood</i> , 2009, 114, 351-351.	1.4	19
730	A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma.. <i>Blood</i> , 2009, 114, 3852-3852.	1.4	11
731	A Phase III Study of Enoxaparin vs Aspirin vs Low-Dose Warfarin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Thalidomide Based-Regimens.. <i>Blood</i> , 2009, 114, 492-492.	1.4	14
732	Incorporation of Thalidomide-Dexamethasone (Thal-Dex) into up-Front Double Autologous Stem-Cell Transplantation (ASCT) for multiple Myeloma: Final analysis of phase II "Bologna 2002" Study.. <i>Blood</i> , 2009, 114, 349-349.	1.4	1
733	Clinical and Prognostic Relevance of Magnetic Resonance Imaging of the Spine in Newly Diagnosed Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation.. <i>Blood</i> , 2009, 114, 4885-4885.	1.4	0
734	Central Nervous System and Intracranial Myeloma: a Retrospective Italian Multicenter Study.. <i>Blood</i> , 2009, 114, 1882-1882.	1.4	1
735	Complete Response to First-Line Bortezomib-Thalidomide-Dexamethasone Therapy in Multiple Myeloma Patients with t(4;14): Analysis of Gene Expression Profile.. <i>Blood</i> , 2009, 114, 2811-2811.	1.4	0
736	Thalidomide and Dexamethasone as Salvage Therapy after First Relapse in Multiple Myeloma: Analysis of Long-Term Outcomes.. <i>Blood</i> , 2009, 114, 4933-4933.	1.4	11
737	A Pilot Study of Lenalidomide and Dexamethasone as First Line Therapy in Patients with Primary Plasma Cell Leukemia.. <i>Blood</i> , 2009, 114, 4951-4951.	1.4	0
738	Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. <i>Leukemia</i> , 2008, 22, 414-423.	7.2	787

#	ARTICLE	IF	CITATIONS
739	Gender-related risk of myocardial involvement in systemic amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2008, 15, 40-48.	3.0	83
740	Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10%549 patients from the International Myeloma Working Group. <i>Blood</i> , 2008, 111, 4039-4047.	1.4	190
741	Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. <i>Blood</i> , 2008, 112, 3107-3114.	1.4	339
742	Superior Complete Response Rate and Progression-Free Survival after Autologous Transplantation with up-Front Velcade-Thalidomide- Dexamethasone Compared with Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2008, 112, 158-158.	1.4	25
743	Superior Rate of Complete Response with up-Front Velcade-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Is Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities.. <i>Blood</i> , 2008, 112, 1662-1662.	1.4	6
744	Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan+Prednisone Versus Melphalan+Prednisone. <i>Blood</i> , 2008, 112, 2778-2778.	1.4	13
745	A Phase IB, Multicenter, Open-Label, Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma. <i>Blood</i> , 2008, 112, 2781-2781.	1.4	17
746	A Phase III Study of Enoxaparin Versus Low-Dose Warfarin Versus Aspirin as Thromboprophylaxis for Patients with Newly Diagnosed Multiple Myeloma Treated up-Front with Thalidomide-Containing Regimens. <i>Blood</i> , 2008, 112, 3017-3017.	1.4	17
747	Bortezomib (VEL) Based Regimens in Multiple Myeloma (MM) Patients with Renal Impairment (RI): A Preliminary Retrospective Italian Multicenter Study. <i>Blood</i> , 2008, 112, 3681-3681.	1.4	1
748	Bortezomib-Thalidomide-Dexamethasone as Primary Induction Therapy for Newly Diagnosed Multiple Myeloma Significantly Decreases Bone Resorption While Sparing Bone Formation as Compared to Thalidomide-Dexamethasone. <i>Blood</i> , 2008, 112, 5117-5117.	1.4	1
749	Economic and Social Burden of Multiple Myeloma in Italy: The Co.Mi.M. Study. <i>Blood</i> , 2008, 112, 2393-2393.	1.4	0
750	Dietary Supplement Vitamin C Significantly Abrogates Bortezomib-Induced Multiple Myeloma (MM) Cell Growth Inhibition. <i>Blood</i> , 2008, 112, 3687-3687.	1.4	0
751	Recent phase III trials in the frontline treatment of multiple myeloma: evaluating their impact on community practice. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, s4-s10.	0.3	1
752	18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone. <i>In Vivo</i> , 2008, 22, 513-7.	1.3	61
753	A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. <i>Haematologica</i> , 2007, 92, 50-55.	3.5	318
754	Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 2434-2441.	1.6	329
755	Neuropathy in multiple myeloma treated with thalidomide. <i>Neurology</i> , 2007, 69, 573-581.	1.1	121
756	Nonmyeloablative allotransplantation for myeloma: light and shade. <i>Blood</i> , 2007, 109, 3134-3135.	1.4	2

#	ARTICLE	IF	CITATIONS
757	Prevention of VTE in multiple myeloma patients. <i>Thrombosis Research</i> , 2007, 120, S133-S136.	1.7	5
758	11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. <i>World Journal of Surgical Oncology</i> , 2007, 5, 68.	1.9	97
759	Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDI)-derived class II-restricted peptides. <i>British Journal of Haematology</i> , 2007, 139, 415-424.	2.5	58
760	Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. <i>European Journal of Haematology</i> , 2007, 80, 071202152247002-???	2.2	4
761	Current status of bortezomib in the treatment of multiple myeloma. <i>Current Hematologic Malignancy Reports</i> , 2007, 2, 128-137.	2.3	9
762	A Prospective, Randomized, Phase III Study of Enoxaparin Versus Aspirin Versus Low-Fixed-Dose of Warfarin in Newly Diagnosed Myeloma Patients Treated with Thalidomide-Containing Regimens.. <i>Blood</i> , 2007, 110, 310-310.	1.4	8
763	Incorporation of Thalidomide into Up-Front Double Autologous Stem-Cell Transplantation (ASCT) for Multiple Myeloma Improves the Outcome in Comparison with Double ASCT without Thalidomide. Analysis of Baseline Factors Predictive of Outcome.. <i>Blood</i> , 2007, 110, 447-447.	1.4	3
764	Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) in Preparation for Autologous Stem-Cell (SC) Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM).. <i>Blood</i> , 2007, 110, 73-73.	1.4	45
765	Superiority of Double over Single Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma and Prognostic Impact of Complete Response: Final Analysis of the Bologna 96 Study.. <i>Blood</i> , 2007, 110, 730-730.	1.4	0
766	Clinical and Prognostic Relevance of Magnetic Resonance Imaging of the Spine in Newly Diagnosed Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 4728-4728.	1.4	0
767	Baseline Thrombophilic Alterations and Risk of Venous Thromboembolism in 266 Multiple Myeloma Patients Primarily Treated with Thalidomide and High-Dose Dexamethasone.. <i>Blood</i> , 2007, 110, 3997-3997.	1.4	1
768	Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone. <i>Blood</i> , 2006, 108, 3951-3952.	1.4	53
769	Proteasome inhibitor bortezomib for the treatment of multiple myeloma. <i>Leukemia</i> , 2006, 20, 1341-1352.	7.2	115
770	International uniform response criteria for multiple myeloma. <i>Leukemia</i> , 2006, 20, 1467-1473.	7.2	2,332
771	Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 525-531.	6.4	135
772	Incidental finding of an 11C-choline PET-positive solitary plasmacytoma lesion. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 1522-1522.	6.4	17
773	Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation. <i>Annals of Hematology</i> , 2006, 85, 549-551.	1.8	4
774	First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2006, 76, 399-404.	2.2	51

#	ARTICLE	IF	CITATIONS
775	The Changing Landscape of Myeloma Therapy. <i>New England Journal of Medicine</i> , 2006, 354, 1076-1078.	27.0	31
776	Poor Outcome With Front-Line Autologous Transplantation in t(4;14) Multiple Myeloma: Low Complete Remission Rate and Short Duration of Remission. <i>Journal of Clinical Oncology</i> , 2006, 24, e4-e5.	1.6	31
777	Gene Expression Profiling (GEP) of Myeloma (MM) Cells To Predict Attainment (near) Complete Response to Primary Therapy with Thalidomide-Dexamethasone (Thali-Dex) for Newly Diagnosed MM.. <i>Blood</i> , 2006, 108, 245-245.	1.4	4
778	Up-Front Thalidomide-Dexamethasone (THAL) and Double Autologous Transplantation (Double TX) for Multiple Myeloma: Comparison with Double TX without Added Thalidomide and Prognostic Implications of Chromosome 13 Deletion and Translocation t(4;14).. <i>Blood</i> , 2006, 108, 3081-3081.	1.4	10
779	Deep Vein Thrombosis in Myeloma: Estimate of Prevalence and Recommendations for Therapy Based upon a Survey of Members of the International Myeloma Working Group (IMWG).. <i>Blood</i> , 2006, 108, 3571-3571.	1.4	2
780	Bone Involvement in Multiple Myeloma Patients Carrying the T (4;14) Chromosomal Translocation.. <i>Blood</i> , 2006, 108, 4996-4996.	1.4	0
781	CKS1B Over-Expression Significantly Predicts for a Lower Rate of Response to Primary Therapy with Thalidomide-Dexamethasone (Thali-Dex) for Newly Diagnosed Multiple Myeloma (MM) Patients.. <i>Blood</i> , 2006, 108, 371-371.	1.4	1
782	Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. <i>Blood</i> , 2005, 106, 35-39.	1.4	333
783	Myeloma therapy: the future is bright. <i>Blood</i> , 2005, 106, 4018-4019.	1.4	1
784	The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. <i>Bone Marrow Transplantation</i> , 2005, 35, 609-617.	2.4	59
785	Neurological toxicity of long-term (>1yr) thalidomide therapy in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2005, 74, 212-216.	2.2	95
786	Bisphosphonates and Osteonecrosis of the Jaws: Incidence in a Homogeneous Series of Patients with Newly Diagnosed Multiple Myeloma Treated with Zoledronic Acid.. <i>Blood</i> , 2005, 106, 3461-3461.	1.4	21
787	Superior Complete Remission/Very Good Partial Remission Rate with Peri-Transplant Administration of Thalidomide-Dexamethasone for Newly Diagnosed Multiple Myeloma.. <i>Blood</i> , 2005, 106, 5474-5474.	1.4	0
788	Prognostic Relevance of t(4;14) and Expression of FGFR3 and TACC3 in Newly Diagnosed Patients with Multiple Myeloma.. <i>Blood</i> , 2005, 106, 5072-5072.	1.4	0
789	Role of 18f-FDG PET/CT in the Management of Multiple Myeloma.. <i>Blood</i> , 2005, 106, 3492-3492.	1.4	0
790	Insuline-Like Growth Factor 1 Is over Expressed in Multiple Myeloma Plasma Cells and Regulates the Expression of the Insuline-Like Growth Factor 1 Receptor.. <i>Blood</i> , 2005, 106, 4363-4363.	1.4	0
791	A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. <i>Thrombosis and Haemostasis</i> , 2004, 92, 1438-1445.	3.4	61
792	Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. <i>European Journal of Haematology</i> , 2004, 73, 98-103.	2.2	105

#	ARTICLE	IF	CITATIONS
793	New insights into the knowledge of graft-versus-myeloma. <i>Blood</i> , 2004, 103, 371-372.	1.4	0
794	Superiority of Double over Single Autologous Stem Cell Transplantation as First-Line Therapy for Multiple Myeloma.. <i>Blood</i> , 2004, 104, 536-536.	1.4	12
795	Thalidomide-Induced Peropheral Neuropathy in Newly Diagnosed and Pre-Treated Multiple Myeloma Patients.. <i>Blood</i> , 2004, 104, 4898-4898.	1.4	0
796	Superiority of First-Line Thalidomide-Dexamethasone over Vincristine-Doxorubicin-Dexamethasone in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.. <i>Blood</i> , 2004, 104, 1489-1489.	1.4	4
797	Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). <i>Haematologica</i> , 2004, 89, 717-41.	3.5	48
798	First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. <i>Haematologica</i> , 2004, 89, 826-31.	3.5	133
799	Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. <i>Blood</i> , 2003, 102, 1588-1594.	1.4	113
800	Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. <i>Blood</i> , 2003, 102, 1927-1929.	1.4	176
801	Relevance of cyclin D1 level in the pathogenesis of multiple myeloma. <i>Blood</i> , 2003, 102, 4245-4246.	1.4	8
802	Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. <i>Blood</i> , 2002, 100, 2272-2272.	1.4	156
803	Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. <i>Haematologica</i> , 2002, 87, 408-14.	3.5	76
804	Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study. <i>Haematologica</i> , 2002, 87, 934-42.	3.5	30
805	Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis. <i>Haematologica</i> , 2002, 87, 1036-40.	3.5	13
806	Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres. <i>British Journal of Haematology</i> , 2001, 113, 209-216.	2.5	307
807	Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation. <i>Haematologica</i> , 2001, 86, 409-13.	3.5	25
808	Alpha-interferon improves survival and remission duration in P-190BCR-ABL positive adult acute lymphoblastic leukemia. <i>Leukemia</i> , 2000, 14, 22-27.	7.2	32
809	Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. <i>Leukemia</i> , 2000, 14, 1310-1313.	7.2	70
810	Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. <i>Blood</i> , 2000, 96, 355-357.	1.4	91

#	ARTICLE	IF	CITATIONS
811	Molecular Remission After Allogeneic or Autologous Transplantation of Hematopoietic Stem Cells for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2000, 18, 2273-2281.	1.6	153
812	Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. <i>Blood</i> , 2000, 95, 2234-2239.	1.4	66
813	Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. <i>Blood</i> , 2000, 95, 2234-2239.	1.4	2
814	Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. <i>Blood</i> , 2000, 96, 355-357.	1.4	1
815	Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. <i>Blood</i> , 2000, 95, 2234-9.	1.4	20
816	Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. <i>Blood</i> , 2000, 96, 355-7.	1.4	31
817	Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. <i>Haematologica</i> , 2000, 85, 930-4.	3.5	27
818	Selection and transplantation of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot study. <i>British Journal of Haematology</i> , 1999, 107, 419-428.	2.5	25
819	Discrepancy between serological complete remission and concomitant new bone lytic lesions after infusion of escalating low doses of donor lymphocytes in multiple myeloma: a case report. <i>Bone Marrow Transplantation</i> , 1999, 24, 685-687.	2.4	14
820	Syngeneic transplantation in multiple myeloma "a case-matched comparison with autologous and allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 1999, 24, 741-745.	2.4	78
821	<i>In vitro</i> treatment with retinoids decreases bcl-2 protein expression and enhances dexamethasone-induced cytotoxicity and apoptosis in multiple myeloma cells. <i>European Journal of Haematology</i> , 1999, 62, 143-148.	2.2	17
822	Clinical and molecular follow-up by amplification of the CDR-III IgH region in multiple myeloma patients after autologous transplantation of hematopoietic CD34+ stem cells. <i>Haematologica</i> , 1999, 84, 397-404.	3.5	14
823	High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. <i>Bone Marrow Transplantation</i> , 1998, 22, 27-32.	2.4	54
824	Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation. <i>Haematologica</i> , 1998, 83, 48-55.	3.5	10
825	Selection and Transplantation of Autologous Hematopoietic CD34+ Cells for Patients with Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 1997, 26, 1-11.	1.3	24
826	Results of a fludarabine induction and interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 1997, 59, 82-88.	2.2	12
827	Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. <i>Blood</i> , 1996, 87, 1625-1634.	1.4	162
828	Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 1996, 88, 4711-4718.	1.4	337

#	ARTICLE	IF	CITATIONS
829	Concomitant Mobilization of Plasma Cells and Hematopoietic Progenitors into Peripheral Blood of Patients with Multiple Myeloma. <i>Stem Cells and Development</i> , 1996, 5, 339-349.	1.0	26
830	Plasma cell P170 expression and response to treatment in multiple myeloma. <i>Haematologica</i> , 1996, 81, 232-7.	3.5	8
831	Peripheral blood stem cell transplantation for the treatment of multiple myeloma: biological and clinical implications. <i>Haematologica</i> , 1996, 81, 356-75.	3.5	4
832	Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 1996, 88, 4711-8.	1.4	79
833	Autoimmune mediated thrombocytopenia associated with the use of interferon-alpha in chronic myeloid leukemia. <i>Haematologica</i> , 1996, 81, 533-5.	3.5	17
834	Solitary plasmacytoma of bone and extramedullary plasmacytoma: Two different entities?. <i>Annals of Oncology</i> , 1995, 6, 687-691.	1.2	89
835	The role of haematopoietic stem cell-supported myeloablative therapy for the management of multiple myeloma. <i>Best Practice and Research: Clinical Haematology</i> , 1995, 8, 795-813.	1.1	7
836	Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma.. <i>Journal of Clinical Oncology</i> , 1995, 13, 1312-1322.	1.6	271
837	An update of prognostic factors for allogeneic bone marrow transplantation in multiple myeloma using matched sibling donors. <i>Stem Cells</i> , 1995, 13, 122-125.	3.2	5
838	Allogeneic bone marrow transplantation for the treatment of multiple myeloma: An overview of published reports. <i>Stem Cells</i> , 1995, 13, 126-131.	3.2	10
839	Autologous stem cell transplantation in multiple myeloma: Results of the european group for bone marrow transplantation. <i>Stem Cells</i> , 1995, 13, 140-146.	3.2	26
840	Prognostic Factors in Autologous Stem Cell Transplantation for Multiple Myeloma: An EBMT Registry Study. <i>Leukemia and Lymphoma</i> , 1994, 15, 265-272.	1.3	53
841	Expression and functional role of c-kit ligand (SCF) in human multiple myeloma cells. <i>British Journal of Haematology</i> , 1994, 88, 760-769.	2.5	42
842	Application of the hydraulic shaking system method to isolation of human pancreatic islets. <i>Transplantation Proceedings</i> , 1994, 26, 3436-7.	0.6	0
843	Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 1993, 51, 93-97.	2.2	28
844	A Randomized Study of MP versus Alternating VAD-VND(N=Mitoxantrone)/MP as Primary Therapy for Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 1992, 7, 75-76.	1.3	0
845	Allogeneic Bone Marrow Transplantation in Multiple Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 1992, 6, 425-435.	2.2	14
846	Allogeneic bone marrow transplantation in multiple myeloma. <i>Hematology/Oncology Clinics of North America</i> , 1992, 6, 425-35.	2.2	4

#	ARTICLE	IF	CITATIONS
847	Allogeneic Bone Marrow Transplantation in Multiple Myeloma. <i>New England Journal of Medicine</i> , 1991, 325, 1267-1273.	27.0	363
848	Evidence for increased intracellular transport of m-sarcosine (alkylating moiety) when combined with two amino acid analogs (PTT-119). <i>Blut</i> , 1990, 61, 311-313.	1.2	2
849	Accelerated hemopoietic recovery after chemotherapy and autologous bone marrow transplantation in hematological malignancies using recombinant GM-CSF: preliminary results obtained in 14 cases. <i>Haematologica</i> , 1990, 75, 551-4.	3.5	8
850	Prognostic variables and clinical staging in multiple myeloma. <i>Blood</i> , 1989, 74, 1774-1780.	1.4	57
851	Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas. <i>Cancer Chemotherapy and Pharmacology</i> , 1989, 23, 123-5.	2.3	11
852	BONE MARROW PURGING FOR MULTIPLE MYELOMA BY AVIDIN-BIOTIN IMMUNOADSORPTION. <i>Transplantation</i> , 1989, 47, 385-387.	1.0	8
853	EVIDENCE THAT LONG-TERM BONE MARROW CULTURE OF PATIENTS WITH MULTIPLE MYELOMA FAVORS NORMAL HEMOPOIETIC PROLIFERATION. <i>Transplantation</i> , 1989, 48, 1026-1030.	1.0	11
854	In vitro growth of myeloma cells*. <i>European Journal of Haematology</i> , 1989, 43, 43-46.	2.2	1
855	Improvement of Durie & Salmon staging for multiple myeloma by adding platelet count as a stratifying variable: A multivariate regression analysis of 163 untreated patients. <i>European Journal of Haematology</i> , 1989, 43, 99-104.	2.2	1
856	Autologous bone marrow transplantation with immunotoxin-purged marrow for advanced multiple myeloma. <i>European Journal of Haematology</i> , 1989, 43, 176-181.	2.2	18
857	High-dose chemoradiotherapy and allogeneic bone marrow transplantation in multiple myeloma. <i>European Journal of Haematology</i> , 1989, 43, 191-195.	2.2	3
858	Normal myeloid progenitors (CFU-GM) in multiple myeloma: a preliminary study in view of autologous BMT. <i>Bone Marrow Transplantation</i> , 1989, 4, 373-7.	2.4	2
859	Acceleration of autologous hematopoietic recovery by GM-CSF after allograft rejection. <i>Haematologica</i> , 1989, 74, 627-8.	3.5	0
860	Prognostic variables and clinical staging in multiple myeloma. <i>Blood</i> , 1989, 74, 1774-80.	1.4	9
861	Improvement of human myeloma stem cell growth in a liquid culture system supplemented with phytohemagglutinin. <i>International Journal of Cell Cloning</i> , 1988, 6, 313-323.	1.6	1
862	Septicaemia after Splenectomy for Hodgkin's Disease: Two Episodes in the Same Patient, 9 and 13 Years after Cure. <i>Acta Haematologica</i> , 1988, 80, 223-223.	1.4	0
863	M ₂ protocol for melphalan-resistant and relapsing multiple myeloma. <i>European Journal of Haematology</i> , 1988, 40, 168-173.	2.2	15
864	Phase II study with a new alkylating agent (PTT-119) in lymphoid malignancies. <i>Haematologica</i> , 1988, 73, 503-8.	3.5	3

#	ARTICLE	IF	CITATIONS
865	Normal and neoplastic plasma cell membrane phenotype: studies with new monoclonal antibodies. <i>Clinical and Experimental Immunology</i> , 1987, 70, 192-200.	2.6	29
866	Solitary Plasmacytoma of the Bone in a Case of Hodgkin's Disease. <i>Acta Haematologica</i> , 1986, 76, 178-180.	1.4	4
867	Bone marrow transplantation in multiple myeloma. <i>Scandinavian Journal of Haematology</i> , 1986, 36, 176-179.	0.0	44
868	Nonsecretory Multiple Myeloma. <i>Acta Haematologica</i> , 1985, 74, 27-30.	1.4	46
869	Meningeal Leukemia Complicating Polymphocytoid Transformation of B-Chronic Lymphocytic Leukemia. <i>Acta Haematologica</i> , 1985, 74, 205-207.	1.4	18
870	Multiple myeloma in young patients. <i>Haematologica</i> , 1985, 70, 464.	3.5	0
871	Lonidamine in the Treatment of Chronic Lymphoid Leukemia. <i>Oncology</i> , 1984, 41, 90-93.	1.9	7
872	BONE MARROW PLASMA CELL INFILTRATION IN MULTIPLE MYELOMA. <i>British Journal of Haematology</i> , 1984, 57, 352-353.	2.5	3
873	BONE MARROW PLASMA CELL INFILTRATION IN MULTIPLE MYELOMA. <i>British Journal of Haematology</i> , 1984, 57, 352-353.	2.5	5
874	Membrane phenotype and functional behaviour of T lymphocytes in multiple myeloma: correlation with clinical stages of the disease. <i>Clinical and Experimental Immunology</i> , 1984, 56, 653-8.	2.6	32
875	Functional behaviour and immunological phenotype of circulating B lymphocytes in multiple myeloma. Studies with pokeweed mitogen. <i>Clinical and Experimental Immunology</i> , 1984, 58, 625-30.	2.6	7
876	Prognostic value of bone marrow plasma cell infiltration in stage I multiple myeloma. <i>British Journal of Haematology</i> , 1983, 55, 683-690.	2.5	28
877	HIGH-DOSE MELPHALAN FOR MULTIPLE MYELOMA. <i>Lancet, The</i> , 1983, 322, 1194.	13.7	3
878	Secondary Cutaneous Plasmacytoma. <i>Acta Haematologica</i> , 1983, 69, 287-288.	1.4	11
879	Staging of chronic lymphocytic leukemia. <i>Blood</i> , 1982, 59, 1191-1196.	1.4	60
880	Glucocorticoid receptor and in vitro sensitivity to steroid hormones in human lymphoproliferative diseases and myeloid leukemia. <i>Cancer</i> , 1982, 49, 623-632.	4.1	28
881	Long-term survival in adult acute leukemia. A multicenter study of 56 patients. <i>Haematologica</i> , 1982, 67, 368-83.	3.5	0
882	IgD myeloma in a young woman. <i>Haematologica</i> , 1982, 67, 760-4.	3.5	2

#	ARTICLE	IF	CITATIONS
883	Peptichemio in multiple myeloma. (Preliminary results). Haematologica, 1981, 66, 208-15.	3.5	8
884	Prognostic factors and survival in multiple myeloma. Analysis of 91 cases treated by melphalan and prednisone. Haematologica, 1980, 65, 437-45.	3.5	9